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ATPase to Breast Cancer Migration Via Correlative SAR

Anniefer Magpusao, Ph.D
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The overall structure of macrocycles is intimately linked to its biological activities
and chemical reactivities. Delineating the factors that control the macrocycle structure
will be very useful in developing novel probes, therapeutics and chemical
transformations. Using a systematic strategy with the [13]-macrodilactones as model
system and a combinational of X-ray crystallography and computational methods, a
general model that explains the effect of stereogenic elements (stereogenic centers and
stereogenic plane) on the overall structure (planar chirality, shape and topology) of the
[13]-macrodilactone was constructed. A specific geometrical arrangement in the
stereogenic centers set the planar chirality (either pS or pR), shape (either ribbon or
alternate) and consequently, the overall topology of substituted [13]-macrodilactones.
This specific geometrical arrangement is fundamentally governed by the preference of
the substituents to be in pseudo-equatorial position. The general model constructed has
useful implications in synthesizing macrocycles with designed structural properties and in
optimizing the biological and pharmacological activities of bioactive macrocycles.
+

The cardiac glycosides ouabain and digitoxin, established Na /K

+

ATPase

inhibitors, were found to inhibit MDA-MB-231 breast cancer cell migration through an

+

+

unbiased chemical genetics screen for cell motility. The Na /K ATPase acts both as an
ion-transporter and as a receptor for cardiac glycosides. To delineate which function is
related to breast cancer cell migration, structure–activity relationship (SAR) profiles of
cardiac glycosides were established at the cellular (cell migration inhibition), molecular
+

+

(Na /K ATPase inhibition), and atomic (computational docking) levels. Correlation of
SAR profiles across these assays established links between cellular activity and specific
protein–small molecule interactions. The antimigratory effect in MDA-MB-231 breast
+

+

cancer cells are directly related to the inhibition of Na /K transport. Specifically, the
orientation of cardiac glycosides at the putative cation permeation path correlates with the
+

Na

+

pump activity and cell migration. Other Na /K

+

ATPase inhibitors that are

structurally distinct from cardiac glycosides also exhibit antimigratory activity,
+

+

corroborating the conclusion that the antiport function of Na /K ATPase and not the
receptor function is important for supporting the motility of MDA-MB-231 breast cancer
cells. Correlative SAR can establish new relationships between specific biochemical
functions and higher-level cellular processes.

!

I.
II.

Rules of Macrocycle Topology: a [13]-Macrodilactone Case Study
A Cardiac Glycoside Activities Link the Ion-transport Function of Na+/K+
ATPase to Breast Cancer Migration Via Correlative SAR

Anniefer Magpusao

A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
at the
University of Connecticut
2015

Copyright © by
Anniefer Magpusao

2015

!

i!

Approval Page
Doctor of Philosophy Dissertation
I.
II.

Rules of Macrocycle Topology: a [13]-Macrodilactone Case Study
A Cardiac Glycoside Activities Link the Ion-transport Function of Na+/K+
ATPase to Breast Cancer Migration Via Correlative SAR

Presented by
Anniefer Magpusao

Major Advisor

_____________________________________________________
Dr. Mark W. Peczuh

Associate Advisor

_____________________________________________________
Dr. Xudong Yao

Associate Advisor

_____________________________________________________
Dr. Alfredo Angeles-Boza

University of Connecticut
2015

ii!

Acknowledgements
My sincerest gratitude to my advisor, mentor and sensei, Dr. Mark W. Peczuh, for his
exceptional guidance through out my training as a chemical biologist. His unbelievable
patience, valuable insights and kind heart allowed me to hear and explore my own voice
as a scientist. Who I currently am and who I will be as a scientist and as a person is a
strong testament of his teaching philosophies. I will forever be indebted to this man, who
I greatly admire for being both a talented scientist and an incredible human being.
I am also very thankful for my committee. To Dr. Yao and Dr. Angeles-Boza, for taking
the time to write a recommendation letter for me and to Dr. Brueckner for his valuable
insights on the macrocycle project. To my former advisor, Dr. Gabriel Fenteany, with
whom I learned a lot about chemical biology, thank you.
The people I met and worked with have tremendously enriched my graduate school
experience and for that, I will always be thankful. To the former PZ lab members:
Jaideep, Rich, Chris and Debjani and to the current PZ lab members: Raghu, Aditya,
Zach, JM and Kelli – these guys are some of the kindest and most helpful people I have
worked with. I specially would like to thank JM and Kelli for all their help in the
macrocycle project. I am grateful for the chance to work with the former Fenteany lab
members: Anwar, Christian, Matt, Junru and Nick. I am very thankful as well to the
collaborators I worked with in all of my projects: George and Dr. Gascon for the cardiac
glycoside project, Trevor and Brandon for the macrocycle project. The most fun I had in
graduate school are the moments I shared with friends I met at UConn. I am sincerely
thankful to Christian, Joan, Daben, Gill, Inus, Kaddie and Ken.
One of the most fulfilling experiences I had in graduate school is the opportunity to
mentor undergraduate students. Being able to contribute in helping students recognize
their potential and watch them grow as a scientist is an experience that I sincerely find
very fulfilling. With that, I would like to thank my previous undergraduate students:
Shannon and Jenaya, for all their help in the screening project; Josh for his contributions
in the cardiac glycoside project; John, for his help in the carbohydrate-fused [13]macrodilactone project and Katie, for a fun summer research on [13]-macrodilactones.
Sometimes, my imagination takes me to a dark place that blurs my perception of the
beauty of life. I am forever indebted to ‘the men’: PZ, Anwar, Fred and Patrick, who
helped me breathe a little easier when I’m drowning in my own thoughts. You have been
the light in my life.
I would like to extend my sincerest gratitude to my parents and family, who have been
my infinite source of love, support and inspiration.
Finally, my deepest gratitude to Patrick Taylor for his unconditional love and support.
For someone who knows me more than I know my self and believes in me when I fail to
see my own worth, I can’t thank you enough. I’m looking forward to spending my life
with you.

! iii!

Table of contents
CHAPTER 1: RULES OF MACROCYCLE TOPOLOGY:
A [13]-MACRODILACTONE CASE STUDY...................................................................1
1.1

Introduction ......................................................................................................2

1.2

Macrocycle and its unique chemical space ......................................................3

1.2.1

The effect of macrocyclization on potency ......................................................3

1.2.2

The effect of macrocyclization on selectivity ..................................................5

1.2.3

Improving pharmacological and pharmacokinetic properties through
macrocyclization...............................................................................................6

1.2.4

Macrocyles can modulate difficult therapeutic targets.....................................9

1.2.5

Summary.........................................................................................................10

1.3

Biological and chemical consequence of macrocycle conformation .............11

1.3.1

Effect of macrocyclic conformations to biological activities.........................12

1.3.2

Effect of macrocycle conformation on its chemical reactivities ....................14

1.3.2.1

Macrocyclic stereocontrol ..............................................................................14

1.3.2.2

Transannular transformations.........................................................................15

1.4

Factors that affect the conformation of macrocycles .....................................17

1.4.1

Conformational analysis of 14-membered macrocyles ..................................18

1.4.2.

Structural properties and conformational analysis of 13-membered
macrocyles......................................................................................................22

1.5

[13]-macrodilactone: motivation, research question, hypothesis,
research design and strategy...........................................................................26

1.5.1

Motivation and research question...................................................................26

1.5.2

Hypothesis, research design and strategy.......................................................27

1.6

Unsubstituted [13]-macrodilactone: synthesis and structural analyses ..........30

1.6.1

Unsubstituted [13]-macrodilactone: synthesis and X-ray crystal structure....30

1.6.2

Introduction to 2D maps of [13]-macrodilactones .........................................34

1.7

Mono-substituted [13]-macrodilactones: syntheses and structural analyses..35

1.7.1

C7 mono-substituted [13]-macrodilactone: Synthesis and X-ray crystal
structure ..........................................................................................................36

1.7.2

Illustration of α-carbon stereogenic center’s control of planar chirality
and demonstration of macrocyclic stereocontrol using chiral HPLC.............40

! iv!

1.7.3

Structural insights on the effect of one stereogenic center on [13]macrodilactone topology ................................................................................42

1.7.4

Origin of the control of [13]-macrodilactone planar chirality by one
stereogenic center ...........................................................................................45

1.8

Di-substituted [13]-macrodilactones: syntheses and structural analyses .......49

1.8.1

C7, C12 - diphenyl [13]-macrodilactones: synthesis and X-ray crystal
structure ..........................................................................................................49

1.8.2

Syntheses of di-substituted [13]-macrodilactones with C2, C7 and C2,
C12 substitution patterns ................................................................................53

1.8.3

Effect of relative cis/trans configuration of substitutents on the topology
of di-substituted [13]-macrodilactones...........................................................57

1.8.4

Effect of substitution pattern on the topology of di-substituted [13]macrodilactones..............................................................................................57

1.8.5

Effect of the interplay between configurations at the stereogenic centers and
stereogenic plane on the topology of di-substituted [13]-macrodilactones....59

1.8.6

Origin of the control of [13]-macrodilactone shape
by two stereogenic centers..............................................................................60

1.8.7

Conclusion: Rules of [13]-macrodilactone topology and its potential
application to other macrocyclic systems.......................................................61

1.9

Experimental Section......................................................................................65

1.10

References ......................................................................................................98

CHAPTER 2: A CARDIAC GLYCOSIDE ACTIVITIES LINK NA+/K+
ATPASE ION-TRANSPORT TO BREAST CANCER MIGRATION VIA
CORRELATIVE SAR .....................................................................................................106
2.1

Introduction to cell migration.......................................................................107

2.2

Small molecule inhibitors of cell migration .................................................108

2.3

Chemical genetics screening for cell sheet migration using a HTS
scratch-wound assay.....................................................................................111

2.4

Chemical genetics screening for breast cancer cell migration .....................114

2.4.1

Results and discussion for screening of [13]-macrodilactone library ..........115

2.4.2

Results and discussion for screening of Chembridge synthetic
compound library..........................................................................................117

2.4.3

Results and discussion for screening of Analyticon natural product
compound library..........................................................................................119

! v!

2.5

Cardiac glycosides as potent and selective inhibitor of Na+/K+ ATPase .....121

2.5.1

Cardiac glycosides – structural features and biological activities................121

2.5.2

Na+/K+ ATPase – a multifunctional protein .................................................123

2.5.3

Context-dependent dual mechanisms of actions of cardiac glycosides........126

2.5.3.1

The classical “Na+ lag” model .....................................................................126

2.5.3.2

The Na+K+ ATPase signalosome model......................................................126

2.6

Investigation of the antimigratory mechanism of action of cardiac
glycosides in MDA-MB-231 breast cancer cell migration...........................129

2.6.1

Motivation and research question.................................................................129

2.6.2

Research design and strategy........................................................................130

2.7

Correlative SAR of ouabain and analogs in cellular and molecular level....134

2.7.1

Semi-synthesis of ouabain analogs...............................................................130

2.7.2

SAR profile of ouabain and analogs in MDA-MB-231 breast cancer cell
migration assay.............................................................................................131

2.7.3

Correlative SAR of ouabain and analogs in MDA-MB-231 breast
cancer cell migration assay (cellular level) and Na+/K+ ATPase assay
(molecular level) ..........................................................................................137

2.8

Correlative SAR of digitoxin and analogs in cellular and molecular
levels.............................................................................................................140

2.8.1

Semisynthesis of digitoxin and analogs .......................................................141

2.8.2

Correlative SAR of digitoxin and analogs in MDA-MB-231 breast
cancer cell migration assay (cellular level) and Na+/K+ ATPase assay
(molecular level) ..........................................................................................142

2.9

Correlative SAR of ouabain and analogs at cellular, molecular and
atomic level ..................................................................................................144

2.9.1

Molecular docking of ouabain and analogs in the α subunit of
Na+/K+ ATPase.............................................................................................144

2.9.2

Correlative SAR of ouabain and analogs in MDA-MB-231 breast
cancer cell migration assay, Na+/K+ ATPase assay, binding energy
and orientation in Na+/K+ ATPase binding site............................................154

2.10

Antimigratory activities of other Na+/K+ ATPase inhibitors that are not
structurally related to cardiac glycosides .....................................................156

2.11

Hypothesis on how cardiac glycoside’s inhibition of Na+/K+ ATPase
leads to inhibition of MDA-MB-231 breast cancer cell migration ..............158

2.12

Conclusion....................................................................................................160

! vi!

2.13

Experimental.................................................................................................162

2.14

References ....................................................................................................168

APPENDIX......................................................................................................................177

! vii!

List of Figures
1-1

Examples of macrocycles .................................................................................2

1-2

Improving potency through macrocyclization..................................................4

1-3

Improving selectivity and controlling small molecule conformation
through macrocyclization .................................................................................6

1-4

Effect of macrocyclic conformations in membrane permeability ....................8

1-5

The shape of the macrocycle is important to its biological activity ...............13

1-6

The shape of the macrocycle is important to its chemical reactivity
as illustrated by macrocyclic stereocontro......................................................15

1-7

The shape of the macrocycle is important to its chemical reactivity
as illustrated by transannular interactions .............................................16

1-8

Representations of cyclotetradecane .....................................................18

1-9

Chemdraw and Ortep diagram of substituted 14-macrolides....................... 21

1-10

12-membered macrocyle apacidin and its 13-membered analogs ........23

1-11

13-membered ring (Stevastelin analog) conformational analysis .........25

1-12

Research design and strategy..........................................................................29

1-13

Structural properties of unsubstituted [13]-macrodilactone ...........................33

1-14

Assignment of planar chirality of [13]-macrodilactones based
on the configuration of the stereogenic alkene plane ............................33

1-15

Construction of the 2D map of [13]-macrodilactone......................................35

1-16

X-ray crystal structure of the enantiomers of C2-methyl
[13]-macrodilactone........................................................................................36

1-17

X-ray crystal structures of the enantiomers of C7-phenyl
[13]-macrodilactone........................................................................................39

1-18

Overlay of 2R,pR and 7S, pR mono-substituted [13]-macrodilactones ..........39

1-19

Chiral HPLC profiles of racemic and chiral [13]-macrodilactone and the
corresponding epoxides ..................................................................................41

1-20

2D maps for the unsubstituted and
mono-substituted [13]-macrodilactones .........................................................44

1-21

Ground-state energy minimizations of conformations of four
stereoisomers of C2-methyl monosubstituted [13]-macrodilactone...............47

1-22

Ground-state energy minimizations of conformations of four
stereoisomers with a methyl substiuent instead of phenyl at C7 ....................48

1-23

Di-substituted [13]-macrodilactones with various substitution patterns. .......49

!viii!

List of Figures
1-24

Crystal structure of diastereomeric trans and cis [13]-macrodilactones,
1-25 and 1-26..................................................................................................51

1-25

Overlays of unsubstituted and di-substituted [13]-marodilactone..................52

1-26

Structural properties of di-substituted [13]-macrodilactones with various
substitution patters and with pR planar chiralities .........................................55

1-27

Structural properties of di-substituted [13]-macrodilactones with various
substitution patters and with pS planar chiralities ..........................................56

1-28

Ground state energy minimization of C7, C12 disubstituted [13]macrodilactones .............................................................................................61

1-29

Thermal ellipsoid plot of 1-19 ........................................................................81

1-30

Thermal ellipsoid plot of Rac-1-22 ................................................................83

1-31

Thermal ellipsoid plot of 1-25 ........................................................................85

1-32

Thermal ellipsoid plot of 1-26 ........................................................................87

1-33

Thermal ellipsoid plot of 1-27 ........................................................................89

1-34

Thermal ellipsoid plot of 1-28 ........................................................................91

1-35

Thermal ellipsoid plot of 1-29 ........................................................................93

1-36

Thermal ellipsoid plot of 1-30 ........................................................................95

2-1

Representative small molecule inhibitors of cell migration .........................110

2-2

Scratch-wound assay of DX-52-1................................................................112

2-3

Representative small molecule probes discovered through high throughput
scratch-wound assay in MDCK cells............................................................113

2-4

Compounds tested for cell vialibility assay..................................................116

2-5

Most promising hits from screening of Chembridge synthetic compound
library for MDA-MB-231 breast cancer cell migration inhibitors ...............118

2-6

Structural properties of cardiac glycosides and representative members
of cardiac glycoside family...........................................................................122

2-7

Cartoon representation of X-ray cystal structure of the high-affinity
Na+/K+ ATPase E2P–ouabain complex........................................................124

2-8

Two models that explain the dual mechanisms of actions of
cardiac glycosides.........................................................................................128

2-9

Research strategy – correlative SAR ............................................................133

2-10

IC50 curves for cell migration inhibition by 2-8 to 2-11...............................136

! ix!

List of Figures
2-11

Correlative SAR of ouabain and analogs at molecular and
cellular levels................................................................................................139

2-12

Correlative SAR of digitoxin........................................................................143

2-13

Crystal structure of Na /K ATPase with bound ouabain ............................146

2-14

Binding site of ouabain.................................................................................147

2-15

Orientation of docked ouabain and analogs in Na+/K+ ATPase ...................150

2-16

Overlay of crystal structure of ouabain-Na /K ATPase complex and
docked ouabian and analogs .........................................................................151

2-17

Critical interactions for inhibition of Na+/K+ ATPase
by cardiac glycoside .....................................................................................152

2-18

Ouabain and analog 2-11 hydrophobic and H-bonding
interactions with amino acid residues in Na+/K+ ATPAse ...........................153

2-19

Correlative SAR at atomic (binding energy), molecular and
cellular level ................................................................................................155

2-20

Correlative SAR at atomic (RMSD), molecular and cellular level ..............156

2-21

Thapsigargin and analog structure................................................................159

A-1

Dose-response curve for ouabain 2-8 effect in
MDA-MB-231 wound closure......................................................................177

A-2

Dose-response curve for ouabain 2-8 effect in
in vitro Na+/K+ ATPase inhibition................................................................178

A-3

Dose-response curve for compound 2-9 effect in
MDA-MB-231 wound closure......................................................................179

A-4

Dose-response curve for compound 2-9 effect in
in vitro Na+/K+ ATPase inhibition................................................................180

A-5

Dose-response curve for compound 2-10 effect in
MDA-MB-231 wound closure......................................................................181

A-6

Dose-response curve for compound 2-10 effect in
in vitro Na+/K+ ATPase inhibition................................................................182

A-7

Dose-response curve for compound 2-11 effect in
MDA-MB-231 wound closure......................................................................183

A-8

Dose-response curve for compound 2-11 effect in
in vitro Na+/K+ ATPase inhibition................................................................184

A-9

Dose-response curve for compound 2-12 effect in
MDA-MB-231 wound closure......................................................................185

+

+

+

+

! x!

List of Figures
A-10

Dose-response curve for compound 2-12 effect in
in vitro Na+/K+ ATPase inhibition................................................................186

A-11

Dose-response curve for compound 2-13 effect in
MDA-MB-231 wound closure......................................................................187

A-12

Dose-response curve for compound 2-13 effect in
in vitro Na+/K+ ATPase inhibition................................................................188

A-13

Dose-response curve for compound 2-14 effect in
MDA-MB-231 wound closure......................................................................189

A-14

Dose-response curve for compound 2-14 effect in
in vitro Na+/K+ ATPase inhibition................................................................190

A-15

Dose-response curve for compound 2-15a,b effect in
MDA-MB-231 wound closure......................................................................191

A-16

Dose-response curve for compound 2-15a,b effect in
in vitro Na+/K+ ATPase inhibition................................................................192

A-17

Dose-response curve for compound 2-16 effect in
MDA-MB-231 wound closure......................................................................193

A-18

Dose-response curve for compound 2-17 effect in
MDA-MB-231 wound closure......................................................................194

A-19

Dose-response curve for compound 2-18 effect in
MDA-MB-231 wound closure......................................................................195

! xi!

List of Tables
1-1

Examples of orally-administered macrocyclic drugs that don’t have
drug-like properties...........................................................................................9

1-2

Point chirality-to-planar chirality correspondence in [13]-macrodilactone ...42

1-3

Crystal data and structure refinement for 1-19 (spider-15025) .....................82

1-4

Crystal data and structure refinement for compound 1-22 .............................84

1-5

Crystal data and structure refinement for compound 1-25 .............................86

1-6

Crystal data and structure refinement for compound 1-26 .............................88

1-7

Crystal data and structure refinement for compound 1-27 .............................90

1-8

Crystal data and structure refinement for compound 1-28 .............................92

1-9

Crystal data and structure refinement for compound 1-29 .............................94

1-10

Crystal data and structure refinement for compound 1-30 .............................96

2-1

Screening of three compound libraries for MDA-MB-231 breast cancer
cell migration inhibitors................................................................................115

2-2

SAR in cell viability assay............................................................................116

2-3

Antimigratory profiles of the most promising hits from the analyticon
natural product compound screening. ..........................................................120

2-4

IC50 values (µM) for the inhibitory activity of ouabain and analogs in
the Na+/K+ ATPase assay and cell migration assay......................................138

2-5

IC50 values (µM) for the inhibitory activity of digitoxin and analogs
in Na+/K+ ATPase assay and cell migration assay .......................................143

2-6

Calculated binding energies and RMSD of ouabain and analogs from
molecular docking experiments and the IC50 values for cell migration
and Na+/K+ ATPase assays...........................................................................155

2-7

Inhibitory effect of Na+/K+ ATPase inhibitors that are structurally
different from cardiac glycoside in the Na+/K+ ATPase assay and the
cell migration assay ......................................................................................157

A-1

Small molecule hits for inhibitors of MDA-MB-231 breast cancer
cell migration from Analyticon natural product library ..............................196

! xii!

List of Schemes
1-1

Synthesis of [13]-macrodilactone .................................................................. 31

1-2

Synthesis of C7-phenyl [13]-macrodilactone ................................................ 37

1-3

DMDO epoxidation of rac-1-22..................................................................... 40

1-4

Synthesis of C7, C12 diphenyl [13]-macrodilactones 1-24 and 1-26 ........... 50

1-4

Synthesis of C2, C12 and C2, C7 di-substituted [13]-macrodilactones ....... 54

2-1

Semi-synthesis of ouabain analogs .............................................................. 135

2-2

Semi-synthesis of digitoxin analogs ............................................................ 141

!xiii!

Chapter 1
Rules of macrocycle topology: a [13]-macrodilactone case study

1

1.1 Introduction
Macrocyles – cyclic molecules of 12 or more atoms – have a staggering array of
structural diversity and biological activities (Fig. 1-1). Ring size can range from 12 to
50+ atoms with chemical composition that can vary from simple repeating units (i.e.
ether linkages and amides) to complex combinations of various functional groups
(alkenes, carbonyls, ethers etc.) in the ring and substituents. This huge structural diversity
(both natural product and synthetic) is reflected to the wide-range of biological activities
(anticancer, antibiotic, antifungal, antiparasitic, antiviral, immunomodulatory) that
macrocycles can modulate as well as the enormous protein families it can target with
disparate mechanisms of action. As evidenced by the long-standing history of the utility
of natural product and synthetic macrocyles as drugs and their unique ability to modulate
various biological activities, macrocycles hold real promise for developing new chemical
probes and novel therapeutics1.
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Fig. 1-1. Examples of macrocycles
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1.2 Macrocycle and its unique chemical space
As a direct consequence of the lower number of freely rotatable bonds, the
macrocyclic ring provides a high degree of conformational pre-organization - one
of the unique and key structural features of macrocycles. With respect to target
engagement of biologically active macrocyles, the conformational pre-organization
of the ring can be used to strategically orient pharmacophoric groups3 and limit
conformational entropy loss upon target binding4. This results in higher affinity
and better selectivity towards specific members of a protein family or even
between different isozymes. Macrocycles also display drug-like physicochemical
and pharmacokinetic properties despite deviating from conventional rules of druglikeness. The next few paragraphs explain how conformational pre-organization
brought about by macrocyclization can generate ligand efficient molecules with
enhanced biological and pharmacokinetic properties.

1.2.1 The effect of macrocyclization on potency
Conformational pre-organization that results from macrocyclization can
improve the potency of acyclic molecules primarily through limitation of the
entropic penalty of forming an inhibitor-protein complex. A molecule needs to
adopt a specific conformation to successfully bind to a protein. Both acyclic and
cyclic molecules can adopt such a bioactive conformation and thus the difference
in the enthalpic contribution to binding is relatively small. However, in contrast to
acyclic molecules, macrocyles have a limited number of conformations (due to
restricted internal bond rotation) and thus have lower entropic penalties when

3

changing from unbound to bound state. This contributes to a higher affinity and
better potency. One compelling example of the effect on potency enhancement of
macrocyclization is the macrocyclization of an acyclic small molecule 1-1 – a
close analog of an inhibitor of farnesyltransferase that is in clinical trial as an
anticancer drug5 (Fig. 1-2). Using transfer nuclear Overhouser effect (trNOE)
NMR, it was observed to be in a folded conformation, which suggests that
macrocyclization, might be beneficial for improving its potency. Indeed, the
cyclized analog 1-3 is 20-fold more potent than the lead 1-1 and impressively
55,000-fold more potent than its direct acyclic counterpart 1-2.

Fig. 1-2. Improving potency through macrocyclization. Two lowest energy
conformations of 1-1 (lower left), consistent with trNOE NMR structure of its
complex with farnesyttransferase, showed it exist in folded form. Rigidification
through macrocyclization (lower right) greatly improved its potency where the
macrocycle 1-3 is 50,000-fold more potent than its direct acyclic counterpart 1-2. The
two figures for the macrocycle conformation were reused with permission.
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1.2.2 The effect of macrocyclization on selectivity
Besides improvement in potency, macrocyclization can also vary the
selectivity profiles of acyclic molecules by fixing or at least reducing the number
of target-specific conformations. By taking advantage of the small difference in
binding site topology between specific members of a protein family or between
various isozymes6, an enhancement in selectivity can be obtained by using the
macrocyclic

ring

as

a

scaffold

to

strategically

orient

pharmacophoric

functionalities at specific three-dimensional locations. A great example is the
development of selective kinase inihibitors (Fig. 1-3)7, one of the most challenging
goals in drug discovery. The notoriously non-selective pan ATPase inihibitors
staurosporine 1-4 and rebeccamycin 1-5 can be made selective by disrupting the
planarity of indolocarbazole lactam ring system - the key pharmacophore of kinase
inhibitors which acts as a mimic of ATP adenine ring. By breaking the central
aromatic ring and controlling the kinase inhibitor’s conformation using various
ring size, Warriner and colleagues developed selective kinase inhibitors with a C2symmetric anti conformation 1-6 (selective towards cAMP-dependent protein
kinase/ protein kinase G/ protein kinase C (AGC) group of protein kinases such as
PKCs) and distorted syn conformation 1-7 (selective towards GSK3β)7.
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a)

b)

Fig. 1-3. Improving selectivity and controlling small molecule conformation
through macrocyclization. (a) Pan ATPase inhitors staurosporine 1-4 and
rebeccamycin 1-5 were made selective through macrocyclization. Ring size
controls the ratio of anti 1-6 and syn 1-7 conformations, which then controls its
selectivity towards specific members of kinases. (b) Docked complex formed by
a protein kinase with inhibitors in various conformations showing how finetuning of macrocyclic conformation can allow access to selective inhibitors. The
macrocycle-protein complex was reused with permission.

1.2.3 Improving pharmacological and pharmacokinetic properties through
macrocyclization
Since poor membrane permeability and metabolic instability are primarily
due to conformational flexibility, restricting the conformational landscape and
fine-tuning the orientation of H-bonding functionalities can significantly enhance
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the pharmacological and pharmacokinetic properties of bioactive molecules. As an
example, for diasteromeric cyclic peptides 1-8 and 1-9 (Fig. 1-4), the most
permeable diastereomer 1-8 adopts a pseudo-symmetric conformation with
internally satisfied hydrogen bonds while the less permeable diastereomer 1-9
adopts a twisted conformation with some H-bonding groups oriented toward the
solvent8. This demonstrates the effect of macrocyclic conformation in membrane
permeability where molecules that can adopt conformations with internal H-bonds
have better passive membrane permeability. Besides locking a specific
conformation, macrocyclization of linear peptides can lead to structural changes
that result in endopeptidase-resistant molecules9. This addresses one of the major
limitations of linear peptides: their susceptibility to undergo proteolysis in the cell
and in the blood.
These are but a few examples (among many reported in the literature)1a, 1d of the
potential of macrocycles and the advantages of macrocyclization for drug
development. Surprisingly, orally administered macrocyclic drugs such as
cyclosporine A, tacrolimus and rapamycin are outside the window of what is
generally considered to be drug-like properties10 i.e. their molecular weights are
often > 500-900 g/mol and their number of H-bond donors (>5) and acceptors
(>10) and polar surface area (>140) are beyond the accepted drug-like spectrum11
(Table 1). Either these bioactive macrocycles are exceptions to the current standard
for drug-like molecules or understanding the unique properties of macrocycles that
brought about these favorable overall pharmacokinetic properties could open up
new rules for developing therapeutic molecules. This avenue has been recently
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explored by Whitty and colleague who analyzed the binding modes of various
macrocycle-protein complexes and proposed some useful guidelines for designing
synthetic macrocycle libraries with structural and physicochemical features that
will likely have high affinity to protein targets and good bioavailability12.

Fig. 1-4. Effect of macrocyclic conformations in membrane permeability.
NMR structural analysis showed that the hydrogen-bonding network in
diastereomer 1-8 (H-bonds are internally satisfied due to a pseudosymmetric conformation) made it more permeable than distereomer 1-9
(some hydrogen-bondng groups are oriented to the solvent due to an
irregular twisted conformation). The macrocycle conformations are reused
with permission.
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Table 1-1. Examples of orally-administered macrocyclic drugs that don’t have drug-like
properties.
Orallyadministered
macrocyclic
drug
Cyclosporin A
Tacrolimus
Rapamycin

MW
(da)

H-bond
donor

H-bond
acceptor

Polar surface
area

1203
804
914

5.2
3.3
4.3

12
3
13

279
178
195

1.2.4 Macrocyles can modulate difficult therapeutic targets
In addition to the upsides of macrocyclization in optimization of biological and
pharmacological properties of molecules, the huge interest in macrocycles is motivated
by their ability to address targets often inaccessible to both standard small molecules and
biologics - the most highly studied of which is the protein-protein interaction13. One of
the various mechanisms by which macrocyles modulate protein-protein interactions is
through either stabilization or destabilization of protein complexes. For example,
epothilone B and its lactam analog Ixabepilone (an antibreastcancer metastasis drug)
stabilize the α-β tubulin dimer14 while halichondin B and its analogs disrupt the
microtubule dynamics by destabilizing these tubulin dimers15. Another mechanism is
through direct structural modification of protein topologies. For example, the cyclic
peptide spiramycin and the macrolide antibiotics erythromycin and carbamycin narrow
the ribosome’s exit tunnel by binding to the inner surface of the ribosomal tunnel16.
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1.2.5 Summary
Clearly, the unique structural properties of a macrocycle allow it to occupy a
chemical space distinct from other molecules or its acyclic counterpart. Conformational
pre-organization provided by limited bond rotation of the ring can be harnessed to
significantly improve not just the potency and selectivity of biologically active molecules
but its pharmacological and overall pharmacokinetic properties as well. Macrocylization
has provided an alternative strategy that medicinal chemists can use to optimize
compound structure more suitable for development as pharmaceuticals. Most macrocyclic
drugs do not fall into the standard categories of drug-like molecules. Understanding how
these macrocycles work can introduce new parameters or rules for developing drugs as
well as deepen our understanding of basic cellular processes such as the mechanisms of
cell permeability. Macrocycles have successfully demonstrated their ability to modulate
difficult targets inaccessible to either standard small molecules or biologics. Besides
expanding the repertoire of chemical space available for development of probe molecules
or drugs in the otherwise crowded-area of enzymatic inhibition, macrocycles also opened
up new biological targets such as protein-protein interaction surfaces. This provided more
options for therapeutic interventions and more areas to explore for mining information on
basic biological and cellular processes. Moreover, the initial efforts in drug discovery
programs such as screening for biologically active molecules can greatly benefit from the
inclusion of macrocyles with various ring scaffoldings in the chemical library screened.
At the heart of all the benefits of macrocyle in medicinal chemistry, basic biology and
drug discovery is the ability to use the macrocyclic ring as a scaffold to strategically
orient pharmacophoric moieties and H-bonding functionality in three-dimensional space.
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If macrocycles as a class is to live up to all its potential, deeper understanding of all the
factors that contribute to the conformational pre-organization of macrocyclic ring needs
to be clearly established. The next sections will specifically discuss the (1) implications
of macrocyclic conformation to its biological activities and chemical reactivities and (2)
the factors that affect macrocylic conformations.

1.3. Biological and chemical consequence of macrocycle conformation
The overall structure of a macrocycle, specifically its ring conformation, is
critical to its biological activity and chemical reactivites. The conformation of the
ring controls the orientation of reactive functionalities and H-bonding groups in the
macrocycle8. Thus, the upsides of macrocylization mentioned in the previous
subsections, i.e. improved binding affinity, better selectivity and paharmakokinetic
properties are intimately linked to ring conformation. In fact, macrocyclization of
acyclic small molecules is only effective if the cyclization results to ground state
cyclized conformation that approximates the optimal bound conformation5. In
addition to the importance of ring conformation to the biological activities of
macrocycles, the overall topology (ring conformation and planar chirality) of
macrocyles is also critical to the stereoselectivity of reactions involving its
functional groups. This is illustrated by examples of macrocyclic diasstereocontrol
and transannular transformations – two useful tools for asymmetric synthesis of
macrocycles and polycyclic compounds. Understanding the factors that affect the
conformation of macrocycles, therefore, is highly important. The next paragraphs
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will discuss, in more detail, the contribution of macrocyclic ring conformation to
the biological activities and chemical reactivities of macrocycles.

1.3.1 Effect of macrocyclic conformations to biological activities
The majority of the improvement in potency, selectivity and overall
pharmacological and pharmacokinetic profile brought about by macrocyclization
can be attributed to macrocyclic ring conformation. Macrocyclization of acyclic,
biologically active molecules is only effective if the correct spatial arrangement of
key binding groups or reactive functionalities is maintained. A direct example of
the effect of conformation in selectivity is illustrated by the macrocyclization of
the pan-ATPase inhibitors staurosporine and rebeccamycin described previously.
Upon, macrocyclization, the C2-symmetric anti conformation is selective towards
the AGC protein kinase group such as PKC while the distorted syn conformation is
selective towards glycogen synthase kinase 3β (GSK3β). Another compelling
example of the contribution of macrocyclic ring conformation in both biological
and physicochemical properties is illustrated by a comprehensive SAR study of a
HSP-90

inhibitor

by

a

group

of

scientists

from

Pfizer17

(Fig.

1-5).

Macrocyclization 1-11 of an anticancer clinical candidate 1-10 gave better
biological activity. Furthermore, simple addition of a methyl group 1-12 resulted in
better pharmacological activities. There are plenty more reports in the literature
that demonstrates the huge contribution of the structural features of macrocyclic
ring to the biological activities of macrocycles1a. What is not clear though is how
specific structural features such as the stereogenic elements on the ring (i.e

12

stereogenic centers and stereogenic axis and planes) affect the conformation of
bioactive macrocycles.
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Fig. 1-5. The shape of the macrocycle is important to its biological activity.
Rigidified version 1-11 of acyclic anticancer clinical candidate 1-10 improved
its biological activity. Simple addition of a methyl group 1-12 with a specific
chirality improved its physiological activity. The methyl group does not seem to
interact with any key amino acids around the binding site (as shown by the cocrystal structure of 1-12 bound to HSP-90) suggesting that the improvement in
pharmacological activity might be due to changes in ring conformation induced
by the added methyl group. The co-crystal structure was reused with
permission.
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1.3.2 Effect of macrocycle conformation on its chemical reactivities
Macrocycles undergo unique chemical transformations such as macrocyclic
diastereocontrol and various transannular reactions where the fate of the
transformation is governed by the ground state conformation of the macrocycle.

1.3.2.1 Macrocyclic stereocontrol
In Still’s pioneering work, alkene-containing macrocycles undergo highly
stereoselective reactions termed macrocyclic stereocontrol18. This control is
primarily due to the orientation of alkene plane (which is perpendicular to the
molecular plane) and thus only one face is accessible to reagents leading to highly
stereoselective reactions (Figure 1-6a). Furthermore, addition of one or two methyl
groups at different positions around the ring can significantly affect the
stereochemical outcome of the reactive functionalities on the ring. Macrocyclic
stereocontrol has been used in a number of key transformations in the synthesis of
natural products. Examples include the total synthesis of cladiellin, a marine
natural

product

where

the

key

transformation

is

the

diastereoselective

dihydroxylation of trisubstituted olefin without the use of assymetric reagent19.
Another example is the synthesis of neopeltolide in which the key transformation
is the stereoselective hydrogenation controlled by the ground state conformation of
the macrocycle20 (Fig. 1-6b).
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Fig. 1-6. The shape of the macrocycle is important to its chemical reactivity as
illustrated by macrocyclic stereocontrol. (a) Macrocycyclic stereocontrol is
brought about by the perpendicular orientation of the alkene plane relative to the
molecular plane. (b) Synthesis of neopeltolide natural product showing the
macrocyclic diasstereocontrol as the key transformation.

1.3.2.2 Transannular transformations
Relatively flexible macrocycles on the other hand, can undergo transannular
interactions leading to intramolecular collapse to form polycyclic molecules (Fig.
1-7). One example is Baran and colleague’s Palau’amine synthesis in which the
macrocycle

conformation

of

macropalau’amine

allowed

for

the

desired

transannular reaction leading to the hallmark trans-5,5 ring system21 (Fig. 1-7a).
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Another example is the olefin isomerisation/intramolecular conjugate addition
reported by Porco and colleague to get a tricyclic ring systems accessed via
transannular cyclization of macrocyclic bis-lactams22 (Fig. 1-7b). The last example
in Fig. 1-7 shows the tandem oxy-Cope/ene reaction reported by Bariault and coworker where the E-olefin geometry of the macrolactone intermediate gave an
exclusive trans ring junction. Furthermore, the more stable ground-state chair-like
conformation of the trans-annular ene reaction transition state resulted to the
preferential formation of the observed tricyclic product23 (Fig. 1-7c).
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Fig. 1-7. The shape of the macrocycle is important to its chemical reactivity as
illustrated by transannular interactions.
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1.4 Factors that affect the conformation of macrocycles
The previous two sections illustrated the contribution of the unique structural
features of macrocycles to its biological and chemical reactivities with emphasis
on the ring conformation as a critical structural feature. The discussion was meant
to explain the motivation behind the importance of understanding, at a
fundamental level, all the factors that affect the stable conformation adopted by the
macrocyclic ring, which is the main goal of our investigation. To put our work into
proper perspective in the field of structural analysis of macroycles, this subsection
will review the current understanding of the factors that control macrocyclic
structure.
A given macrocycle can exist in various stable conformations but only a few are
low enough in energy to be accessible at room temperature. In general,
conformational biasing in macrocycles is governed by their tendency to minimize
transannular nonbonded repulsions. For macrocycles with various substitutions and
unsaturated groups such as alkenes, esters and amides, the rules with respect to
stable conformations adopted by the skeleton are more complex. Factors such as
ring size, chemical composition of the ring skeleton (type and arrangement of
functional groups, unsaturation, and planar units) and configuration of stereogenic
elements (stereogenic planes and stereogenic centers around the ring) exert
considerable contributions to the macrocycle conformation.
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1.4.1 Conformational analysis of 14-membered macrocyles
The 14-membered macrocycles are one of the most highly studied systems
due to the prevalence of 14-membered bioactive natural products24. According to
Dale’s pioneering work, 14-membered macrocycles should exist predominantly in
a ‘rectangular’ diamond-lattice [3434] conformation25 (Fig. 1-8b,c). Dale’s
analysis showed that cyclotetradecane is the first cycloalkane after cyclohexane
that can have a strain-free conformation in the form of a diamond-lattice [3434]. It
is composed of two ‘three-bond’ sides and two ‘four-bond’ sides, hence the name
[3434]. Indeed, cyclotetradecane exists only in this [3434] conformation in solid
state as supported by XRD26 and solid state

13

C NMR27. In liquid state however, it

loses its conformational homogeneity and exists in several conformations with the
[3434] conformation being the most predominant one as supported by low temp
NMR analysis28, and vibrational spectroscopy29.

a)

b)

+60 180

c)

+60

+60

+60

180

180

180

180

-60

-60
-60

-60

Fig. 1-8. Representations of cyclotetradecane. (a) Chemdraw 2D representation.
(b) Dale’s [3434] representation of triangular diamond-lattice conformation
where torsion angles are represented as positive and negative numbers. (c)
Schematic drawing of the actual crystal structure of cyclotetradecane from
reference 25.
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Dale also predicted that replacing the methylene groups in the
cyclotetradecane ring with an oxygen atom or groups such as an amine, carbonyl
or imine would cause only minimal perturbation on the diamond-lattice
conformation.

Indeed,

1-oxa-30,

1,3,8,10-tetraoxa-31,

1,8-diaza-32,

cyclotetradecanone33, cyclotetradecane-1,8-dione34, and tridecanolactone34 gave
the same [3434] diamond-lattice conformation. Moreover, insertion of either a
ester35 or amide36 group into the ring gave the same [3434] conformation as the
most stable conformation and with the lactam and lactone groups in s-trans
conformation25 in both solution35 and solid state36b.
More complex 14-memebered macrocycles with various substitutions and in
combination with either a amide28 or ester35 group in the ring gave a more complicated
correlation between substitution pattern, planar units (lactam or lactone) and macrocyclic
conformation. Dale’s analysis predicted that substitutions on 14-memberd macrocycles
would not affect the preferred diamond-lattice [3434] conformation. Moreover, he
predicted that the substituents could only occupy exterior (pseudo-equatorial) positions
due to large transannular interaction associated with interior (pseudo-axial) position.
Indeed, substituents around 14-membered macrocycles only occupy exterior positions.
However, certain substituted 14-membered macrocycles did not adopt the [3434]
conformation28,

35

. Highly substituted 14-macrolides gave a different lowest energy

conformation (i.e., [3335], [3344] etc.) distinct from the predicted [3434] conformation as
supported by both XRD and molecular mechanics calculation35 (Fig. 1-9). The
conformation seemed to depend on the number and configuration of substitutions and the
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substitution pattern. Similarly, using various techniques in both solid and liquid state,
conformational analysis of 14-membered diketal dilactam36a painted a more complex
relationship between planar units, stereogenic centers and conformation. In this ring
system, the conformations depend on whether the macrocycle is chiral or achiral and on
the stereochemistry of the substituents. Based on these reports, the rules governing the
conformational preference of highly substituted 14-macrocycles are more complex than
what Dale’s analysis predicted. The substituents around the ring clearly affect the stable
conformation adopted by the 14-membered macrocycle where various conformations
distinct from the diamond-lattice [3434] conformation can be accessed depending on the
number and configuration of stereogenic centers and the substitution pattern. How these
stereogenic elements control the conformation of macrocycles, however, is not currently
understood.
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[3434]

[34’3’4’]

[3335]

[3344]

Fig. 1-9. Chemdraw and Ortep diagram of substituted 14-macrolides that adopted
various conformations, with some that are distinct from the diamaond-lacttice [3434]
conformation. The conformation seemed to depend on the number and configurations
of stereogenic center around the ring and the substitution pattern.
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1.4.2. Structural properties and conformational analysis of 13-membered
macrocyles
Although they have not been investigated as thoroughly as 14-membered
ring systems, 13-membered macrocyles have unique structural features. One report
(among few) showed that in contrast to strained 12-membered cyclic tetrapeptides
(CTPs), 13-membered CTPs can adopt a unique architecture that is more rigid,
easier to cyclize, hydrolytically more stable and are conformationally homogenous
in polar solvents37 (Fig. 1-10). 12-membered CTPs have unfavorable strain due to
the four trans-amide bond restraints. Addition of a methylene to a 12-membered
ring CTPs by using a β-amino acid rotates one of the amide bonds that results to a
more rigid structure. Because of the conformational homogeneity of 13-membered
CTPs, 13-membered versions of the 12-membered natural product apacidin
(HDAC inhibitor) were used to mine three-dimensional pharmacophoric features
necessary for designing isoform-selective HDAC inhibitors38. These studies
illustrate the potentials of the unique structural features of 13-membered
macrocyles

and

reiterate

the

importance

of

understanding

macrocyclic

conformation in developing useful probe molecules.
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Fig. 1-10. 13-membered analogs 1-14 of the 12-membered natural product
Apacidin 1-13 are conformationally homogenous in solution. The figure for the
conformation of 13-membered macrocycle was reused with permission.
Compared to 14-membered macrocycles, the conformational preference of
13-membered macrocycles is less understood probably because of the lesser
population of bioactive 13-membered macroyclic natural products24. A couple of
studies on stevastelins – a 13-membered antiviral cyclic peptide that targets
Vaccinia VH1 phosphatase – looked at the conformations in solution of a series of
its diastereomeric analogs (Fig. 1-11). Using force field conformational searches
for one force field constrained by variables from the NMR data, one report found
that these diastereomers exist as a single conformational family in solution39 (Fig.
1-11b). Using another method, NMR analysis of molecular flexibility in solution
(NAMFIS), the same set of diastereomers were found to adopt different
conformations in solution40 (Fig. 1-11c). The accuracy of conformational analysis
of macrocycles using NMR and computational methods is highly dependent on the
type of conformational search methods used (different search methods have
different parameters) and the condition and type of NMR analysis. Although the
two

studies

found

contradictory

results

between

the

homogeneity

and
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heterogeneity of the conformations of the studied series of diatereomers in solution,
both agreed that using D-ser reduces conformational mobility in stevastelins and
more importantly, subtle changes in stereochemistry at one or two chiral centers
can greatly affect the conformational preference of this 13-membered macrocycles.
Similar to 14-membered macrocycles, the specific contribution of configuration at
a stereogenic center or combination of stereogenic centers and substitution pattern
to the low energy conformation adopted by the macrocycle is not well understood.
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Fig. 1-11. 13-membered ring (Stevastelin analog) conformational analysis. (a) Chemdraw of the natural product stevastelin D3 and
the core structure of its analogs. Blue font color emphasizes the structural difference between the two macrocycles. Conformational
analysis of stevastalin diastereomers using two different combinations of NMR and computational methods led to two different
conclusions regarding the homogeneity (b) – diastereomers 1-16 exists as a single conformational family in solution - and
heterogeneity (c) – the same diastereomers of 1-16 exists in different conformations in solution - of the conformations of the
diastereomers in solution. Both analyses agreed that using D-ser 1-17 led to a homogenous conformation in solution. Figures for the
different conformations were reused with permission from ref 38 and 39.

1.5 [13]-macrodilactone: motivation, research question, hypothesis, research
design and strategy

1.5.1 Motivation and research question
As emphasized in the introduction, macrocycles as a class of molecules have
unique structural properties that allow them to occupy a chemical space distinct from
other molecules or their acyclic counterparts. This unique chemical space has great
potential in biology (developing novel chemical probes, and therapeutics) and chemistry
(developing novel chemical transformations and asymmetric reactions). The unique
structural properties are intimately linked to ring conformation. Thus, understanding the
factors that control the conformation of the ring will be very useful. Dale’s pioneering
work on 14-membered macrocycles greatly simplified its conformational analysis but is
not applicable to more complex, highly substituted 14-membered macrocyclic systems.
13-membered macrocycles, although possess interesting structural and biological
properties are less studied. In both 13-membered and 14-membered macrocycles or
probably, in macrocycles as a class in general, one of the important areas that need
clarification is how the stereogenic elements (stereogenic planes and stereogenic centers
around the ring) contribute to the stable low-energy conformation adopted by the
macrocyle. Although, many have observed that subtle changes in the stereochemistry in
one or two chiral centers have tremendous impact on conformation, as far as we know, no
one has figured out how this happens. We think that this is because most of the reports
used macrocyclic systems with multiple stereogenic centers already set in the ring. Such
is the case for cyclic peptides, which is the macrocyclic system used by majority of
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scientists who work in this field. We thought that in order to really understand the
contribution of stereogenic centers on macrocyclic conformation, a systematic study is
required. Starting from a ring system without stereogenic center followed by systematic
incorporation of one streogenic center at a time at specific position around the ring can
help pinpoint the exact contribution of specific stereogenic center and combinations
thereof. One of the overarching goals in our lab is to understand, at a fundamental level,
all the factors that affect the overall structure of macrocycles.

1.5.2 Hypothesis, research design and strategy
Currently, we use the [13]-macrodilactone as our model system to
systematically explore the parameters that govern its structure. Consider the
unsubstituted macrocycle 1-19 in Figure 1-12. Atoms of the ring are categorized as
part of a planar unit such as the two esters (atoms C4-C7 and C12-C2) and the Ealkene (C8-C11) or elsewhere (atom C3). Connections between planar units can be
through a bond, as in the connection of the C4-C7 ester with the alkene, or through
an atom (and its associated bonds), as between the two ester units which are
connected by C3. Starting with the C12-C2 ester unit, a motif of planar unit, atom,
planar unit, planar unit develops (Fig. 1-12).
We look at the contribution of the interplay between planar units (2 esters and an
e-alkene) and stereogenic centers around the ring on its overall structure in solid state
using X-ray crystallography. We describe the three-dimensional structure of the [13]macrodilactone using three terms - planar chirality, shape and topology. The planar
chirality refers to the configuration of the embedded stereogenic E-alkene plane. We use
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shape to describe the conformation or geometry adopted by the ring skeleton regardless
of the substituents. We use topology as a more encompassing description of the overall
structure of the [13]-macrodilactone because it takes into consideration all the structural
features i.e., planar chirality, shape and the orientation of functional groups in the ring
and in the substituents.
Our major hypothesis is that the numbered atoms (Fig. 1-12) – we call key atoms
- that are positioned at the edge of each planar unit can greatly influence the overall
topology of the macrocycle primarily due to steric considerations. If the configuration of
a substituent at any of the key atoms results in ring strain, the planar units will rearrange
themselves forcing the macrocycle to adopt a different shape. To test this hypothesis, we
systematically incorporate one and two substituents at a time around the key atoms on the
ring using a synthetic route we have previously reported – a series of acylation of various
diol using various pentenoic acid followed by ring closing metathesis of the
corresponding diene41. This systematic incorporation of stereogenic centers will allow us
to determine the actual contribution of the configuration at one or a combination of
stereogenic centers as well as the substitution pattern on the overall topology (planar
chirality, shape and functional group orientations) of [13]-macrodilactone in solid state
using X-ray crystallography. Using this strategy, we have previously reported a series of
observations on mono-substituted41b, 41d and di-substituted 13-macrodilactones41c, 41d .
In this chapter, we construct a general model that explains the topology of our
[13]-macrodilactones. The model collects the factors that govern the topology and offers
a physical rationale behind them. Our analysis will focus especially on how the
stereogenic centers at key atoms affect the topology of [13]-macrodilactones. We use a
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combination of crystallographic data along with computational methods to categorize the
topologies and to understand their origins. We think that our systematic approach to
dissect the principles that govern the structural preference of [13]-macrodilactones will
be helpful in synthesizing macrocycles with designed structural properties. Although our
observations are primarily based on X-ray crystallographic data and some computational
methods and are thus bound by the limitations inherent to these types of analyses, the
fundamental information they revealed about the [13]-macrodilactone systems has value
and might be applicable to other ring systems with similar chemical composition.

Fig. 1-12. Research design and strategy

29

1.6 Unsubstituted [13]-macrodilactone: synthesis and structural analyses
Our goal has been to systematically assess the contributions of specific
stereogenic centers on the topology of [13]-macrodilactones. All our previous reports
were focused on substituted [13]-macrodilactones41b-d. To gain an understanding of the
inherent conformational preferences of the macrocycle, however, we synthesized and
characterized the unsubstituted [13]-macrodilactone 1-19. Its structure serves as a
reference for comparison to all the subsequent substituted structures. In this way, we
could assign the effect of the configuration of stereogenic centers at the key atoms on the
overall structure of the [13]-macrodilactone.

1.6.1 Unsubstituted [13]-macrodilactone: synthesis and X-ray crystal structure
The unsubstituted [13]-macrodilactone 1-19 was synthesized using the route we
previously reported41b-d and characterized using X-ray crystallography. The starting 1,3
propanediol was run though a series of acylation using pentenoic acid to get the
diacylated diene 1-18. This acyclic precursor was closed via a ring closing metathesis
using Grubb’s 2nd generation catalyst (Scheme 1-1).
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Scheme 1-1. Synthesis of [13]-macrodilactone

Unsubstituted [13]-macrodilactone 1-19 is crystalline and its structure was
characterized using X-ray crystallography. Like the other [13]-macrodilactones we
previously reported, 1-19 is rigidified by three four-atom planar units: two ester
planes of atoms 4,5,6,7 and 2,3,12,13 and the alkene plane of atoms 8,9,10,11.
These planar units limit the number of freely rotatable bonds in the macrocyle (Fig.
1-12 and 1-13). The planar units arranged themselves in a non-coplanar manner
around C3, an sp3-hybridized carbon that is not a part of any planar units. This
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atom is called a hinge atom because it acts as a hinge in which the two ester planes
can rearrange themselves. The macrocycle adopted a shape that, when viewed
from the side, looks like a ribbon and, from the top, looks like a triangle (Fig. 113). We call this shape ‘ribbon’ because the planar units wrap around each other in
a manner that resembles a ribbon. This result establishes that the globally preferred
shape for the [13]-macrodilactone is the ribbon shape. Importantly, 1-19
crystallized as a racemic mixture of enantiomeric macrocycles that exhibit planar
chirality (Figs. 1-13, 1-14). E-alkene containing cyclic molecules such as Ecycylooctene shows planar chirality that is solely due to the streogenic E-alkene
plane. Planar chirality in macrocycles was also observed for bisbenzimidazole
macrocycles with chiral cyclic E-alkene linkage that hardly flips into its
enantiomeric structure at room temperature42. Furthermore, for bisbenzimidazole
macrocycles, the E-alkene planar chirality was effectively transferred to the S axial
chirality of the bisimidazole framework and the P helical chirality of the cyclic Ealkene43. Both pS and pR planar chiral macrocycles - the planar chirality was
assigned based on the configuration of the chiral E-alkene plane (Fig. 1-14) - are
present in the unit cell for 1-19, proving that the [13]-macrodilactone motif creates
an element of stereogenicity on its own.
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Fig. 1-13. Structural properties of unsubstituted [13]-macrodilactone. Crystal structure
show the planar enantiomers - pS and pR. Numbered atoms show the three 4-atom planar
units. Top figures show the triangular shape when viewed from the top of the molecular
plane. Bottom figures show the ribbon shape when viewed on the side of the molecular
plane.

Figure 1-14. Assignment of planar chirality of [13]-macrodilactones based on the
configuration of the stereogenic alkene plane.
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1.6.2 Introduction to 2D maps of [13]-macrodilactones
In order to easily and systematically account for the similarities and differences in
shape and planar chiralities between each [13]-macrodilactones, we have adapted a
graphical representation previously developed for porphyrin systems44. The map shows
the deviation of each atom from a molecular plane defined by three specific atoms: C3,
C13 and C6. Deviations of each atom from the plane were measured using the software
Mercury, available from CCDC. The y-axis corresponds to the relative distance of each
atom with respect to the molecular plain and the positive or negative sign refers to the
atoms above or below the specified plane (Fig. 1-15). Using the pS enantiomer of [13]macrodilactone 1-19 as an example (Fig. 1-15), the plane consisting of the C3, C13, and
C6 (coded in black) atoms were chosen to define the macrocyclic plane. To respresent a
three-dimensional structure in two-dimensions, the macrocyle was treated as an acyclic
structure by cutting through the C3 atom. This leads to a two-dimensional map where the
C2-C3 bond represented as the first 2 points on the graph followed by the succession of
atoms that constitute the ring skeleton with the C4-C3 bond represented as the last points
in the graph. The same treatment was used to graphically represent the crystal structures
of all the [13]-macrodilactones. These maps help to simplify the visualization of the
similarities and differences in the shape and planar chirality between various [13]macrodilactones that would otherwise require multiple figures to illustrate the different
perspectives in looking at a three-dimensional structure.
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Figure 1-15. Construction of the 2D map of [13]-macrodilactone

1.7 Mono-substituted [13]-macrodilactones: syntheses and structural analyses
To look at the effect of one stereogenic center on the topology (planar chirality
and shape) of the [13]-macrodilactone, we synthesized mono-substituted versions (with
stereogenic centers at either C2 or C7) and followed on the subsequent structural changes
using X-ray crystallography. Our lab previously synthesized the C2-substituted [13]macrodilactone 1-20 and found that specific configuration at C2 gave a specific planar
chirality where an R and S configuration gave a pR and pS planar chirality,
respectively41b (Fig. 1-16). A new monosubstituted [13]-macrodilactone with a phenyl
substitutent at C7 position was synthesized and characterized to look at the effect of
incorporating a stereogenic center at the carbon alpha to the carbonyl41d.
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Fig. 1-16. X-ray crystal structure of the enantiomers of C2-methyl [13]-macrodilactone
1-20.
1.7.1 C7 mono-substituted [13]-macrodilactone: Synthesis and X-ray crystal structure
C7-phenyl mono-substituted [13]-macrodilactone 1-22 was synthesized using the
same synthetic route (Scheme 1-2) we established previously. 1,3- propanediol was first
acylated with pentenoic acid using DCC and DMAP to yield the 3-hydroxypropyl 4pentenoate in 56% yield. A second acylation with racemic 2-phenyl-4-pentenoic acid on
the remaining free hydroxyl group gave diacylated product (80%). Racemic macrocycle
1-22 (rac-1-22) arose via RCM of the diacylated product using Grubbs’ secondgeneration catalyst (58%).
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Scheme 1-2. Synthesis of C7-phenyl [13]-macrodilactone

Similar to the C2-methyl compound 1-20, the configuration at the α-stereogenic
center (C7) guides the topology of [13]-macrodilactones. Macrocycle rac-1-22 was
isolated as a crystalline solid, which was subjected to X-ray crystallographic analysis.
Since racemic 2-phenyl-4-pentenoic acid was used in the synthesis, the corresponding
macrocycle was also racemic. Present in its crystal lattice, therefore, were both
enantiomers of the [13]-macrodilactone 1-22. The C7 stereogenic center with R
configuration resulted in a macrocycle with only pS planar chirality while the C7 S
enantiomer gave rise to only pR planar chirality (Fig. 1-17). Transannular nonbonded
interactions where sterically demanding substituents attached to the stereogenic center are
situated away from the macrocyclic ring itself are minimized in this conformation. The
enantiomers have the same shape but different planar chirality and, thus, different
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topologies. Here, ‘topology’ includes the mirror-image orientations of the phenyl
substituents and the carbonyl groups in three-dimensional space. It is important to note
that the shape adopted by the backbone of 1-22 was similar to that of C2-substituted
macrocycle 1-20 (RMSD = 0.0454, using 2R,pR-1-20 and 7S,pR-1-22) (Fig. 1-18),
supporting that this shape is generally the most stable conformation for the monosubstituted [13]-macrodilactones regardless of the location of the substituent (either C2 or
C7) or the type of substituent (methyl or phenyl). Both C2 and C7 are at the junction of
two planar units (Figure 1-12 and 1-13) corroborating the hypothesis that these positions
are key stereogenic centers that direct the planar chirality, and hence the topology of
[13]-macrodilactones.
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Fig. 1-17. X-ray crystal structures of the enantiomers of C7-phenyl [13]-macrodilactone
1-22.

Fig. 1-18. Overlay of 2R,pR - 1-20 (pink) and 7S, pR - 1-22 (cyan) with an RMSD of
0.0454 showing common ‘triangular’ or ‘ribbon’ [13]-macrodilactone shape.
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1.7.2 Illustration of α-carbon stereogenic center’s control of planar chirality and
demonstration of macrocyclic stereocontrol using chiral HPLC
To illustrate that it is indeed the configuration at the α-stereogenic center that
dictates the planar chirality adopted by the [13]-macrodilactone, an enantioenriched
version of 1-22 (7S,pR) was synthesized using 2S-phenyl-4-pentenoic acid (90% ee).
Chiral HPLC profiles of rac-1-22 and 7S,pR-1-22 are shown in Fig. 1-19. The
macrocycle derived from racemic pentenoic acid resulted in a 50:50 mixture of [13]macrodilactones.

The

one

synthesized

from

2S-phenyl-4-pentenoic

acid

was

enantioenriched, with an ee of 60%. We attributed the deterioration of enrichment
between the acid and macrocycle to racemization of the chiral diester under the acylation
conditions during diene formation. Nonetheless, the transfer of point chirality from the
starting acid to the planar chirality observed in macrocycle 7S,pR-1-22 corroborated our
original conclusion about the control of planar chirality in [13]-macrodilactones by the αstereogenic center. DMDO epoxidation

of rac-1-22 (Scheme 1-3) gave only one

diastereomer of 1-23 as a pair of enantiomers (Figure 1-19). For 7R,pS-1-22, the
enantioenrichment of the alkene was maintained after epoxidation to 1-22. Reactions of
these [13]-macrodilactones therefore exhibit a high level of macrocyclic diastereocontrol.
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Scheme 1-3. DMDO epoxidation of rac-1-22.
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Fig. 1-19. Chiral HPLC profiles of racemic (pink) and chiral (blue) [13]-macrodilactone
1-22 and the corresponding epoxides 1-23.
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1.7.3 Structural insights on the effect of one stereogenic center on [13]-macrodilactone
topology
Table 1-2. Point chirality-to-planar chirality correspondence in mono-substituted [13]macrodilactones
Mono-substituted 13macrodilactones
C2-methyl
C7-phenyl
(if phenyl is given the 3rd
priority in assigning
configuration)

Point chirality

Planar chirality

2S
2R
7R (7S)

pS
pR
pS

7S (7R)

pR

The structures of the two mono-substituted [13]-macrodilactones (with a
stereogenic center at either C2 or C7) demonstrated that the configuration at the
center guides the planar chirality of [13]-macrodilactone where one configuration,
either R or S only gave one planar chiral enantiomer, pS or pR. In the case of the
C2-methyl [13]-macrodilactone 1-20, the 2R center gave rise to the pR planar
chirality. For 1-22, the 7S configuration gave rise to the pR planar chirality. This
observation is further supported by the fidelity of formation of only one planar
chirality during cyclization of a homochiral diene. At first glance, it may seem that
there is no correspondence between the configuration at the stereogenic center and
the planar chirality of the macrocycle. However, if the substituent (methyl, phenyl,
etc.) on the stereogenic center is given the third priority by convention, then the 7S
configuruation of 1-22 becomes 7R (Table 1-2). It suggests that specific geometry
of groups around the center (not necessarily equivalent to CIP R and S
designations) does in fact set the planar chirality of the ring regardless of the
substituent type (either methyl or phenyl) or location (either C2 or C7). If any
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substituent on the ring will be given the third priority when assigning configuration
at point chirality, then the rule for point-to-planar chirality in mono-substituted
[13]-macrodilactone systems will be R-to-pR and S-to-pS (Table 1-2). Moreover,
the unsubstituted [13]-macrodilactone 1-19 and the two monosubstituted 1-20 and
1-22 all adopted the same ribbon or triangular shape as illustrated by the 2D maps
(Fig. 1-20). Also note that the substituents in 1-20 and 1-22 are all positioned
outside of the ring or are in ‘pseudo-equatorial’ positions as evident in their crystal
structure and in the 2D maps.
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a)

Å

b)

Å

c)

Å

Fig. 1-20. 2D maps for the unsubstituted [13]-macrodilactone (a) 1-19 and monosubstituted [13]-macrodilactones (b) 1-20 and (b) 1-22.
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1.7.4 Origin of the control of [13]-macrodilactone planar chirality by one stereogenic
center
Since the unsubstituted [13]-macrodilactone 1-22 contains an inherent planar
chirality (an element of stereoisomerism), addition of another stereogenic element
such as a stereogenic center could give rise to up to four stereoisomers. Combining
specific isomers with either pS or pR planar chirality for each R, S configuration at
the stereogeic center would give pS,S, pS,R, pR,S, and pR,R isomers. In cases
where the [13]-macrodilactone had only one stereogenci center, we only isolate
two stereoisomers - a pair of enantiomers – in which each configuration (either S
or R) at stereogenic center gave rise to only one out of the two possible planar
chiralities (pS or pR). This observation hypothesized that the energy associated
with the conformation of the two stereoisomers we didn’t isolate are higher energy
conformations.
Ground-state energy minimization - using a dispersion corrected density functional
(MO6-2x) paired with a robust basis set (6-31+G(d,p)) - was employed to look at the
energetics associated with the conformations of 1-20 and 1-22 (Fig. 1-21 and 1-22 ). The
C7-phenyl group in 1-22 was replaced with a methyl group to have the same number of
atoms when comparing the energies for each macrocyels. The planar stereoisomers of 120 (2S, pS and 2R, pR) have degenerate energies and thus were isolated and crystallized
as a racemate of planar enantiomers (Figs. 1-16 and 1-21). The other two stereoisomers
(2S, pR and 2R, pS) that were not isolated (and probably were not formed) have
degenerate energies as well but are 3.5 kcal/mol higher than their respective
diastereomers (Fig. 1-21). The specific combinations of 2S, pR and 2R, pS results in a
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macrocyclic conformation in which the substituents are both in pseudo-axial position as
opposed to pseudo-equatorial positions of the substitutents of stereoisomers 2S, pS and
2R, pR. A pseudo-axial position promoted transannular nonbonding interactions that
resulted to a higher energy conformation. Similar observations were seen for the
energetics of 1-22 but with a slightly lower energy difference (2.4 kcal/mol) between the
isolated isomers (7R, pR and 7S, pS – with a methyl substituent instead of phenyl) and the
other two potential isomers (7S,pR and 7R, pS - with a methyl substituent instead of
phenyl) (Figure 1-22). It appears that for mono-substituted [13]-macrodilactones,
regardless of substituent position (either C2 or C7) or type of substituent (either methyl or
phenyl), the preference for a pseudo-equatorial position governs the selectivity for a
specific planar chirality conferred by the configuration at the stereogenic center.
Moreover, the shape adopted by the mono-substituted [13]-macrodilactones 1-20 and 122 is the same triangular or ribbon shape observed for the unsubstituted [13]macrodilactone 1-20 showing that addition of one substituent in the ring does not affect
the shape of [13]-macrodilactones.
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Fig. 1-21. Ground-state energy minimizations of conformations of four
stereoisomers of 1-20.
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Fig. 1-22. Ground-state energy minimizations of conformations of four stereoisomers of
1-22 with a methyl substiuent instead of phenyl.
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1.8 Di-substituted [13]-macrodilactones: syntheses and structural analyses
Subtle changes in stereochemistry of substituents can greatly influence the
conformational preference and biological activities of macrocyles as discussed in the
introduction. This observation has confounded medicinal chemists for a long time. Our
systematic approach in using the [13]-macrodilactone systems lends itself to the
possibility of addressing how the stereogenic centers around the macrocyle contributes to
its overall structure. To explore some underlying principles on the effect of combinations
of two stereogenic centers and substitution pattern on the planar chirality, shape and
overall topology of [13]-macrodilactones, we used the same synthetic route we have
previously reported to synthesize di-substituted macrocycles with various substitution
patterns.

Fig. 1-23. Di-substituted [13]-macrodilactones with various substitution patterns. From
left to right: 7,12; 2,4; 2,7; 2,12 di-substituted 13-macrodilactones.
1.8.1 C7, C12 - diphenyl [13]-macrodilactones: synthesis and X-ray crystal structure
C7 and C12 di-substituted [13]-macrodilactoens were synthesized to explore how
the α-stereogenic centers work together to guide both the shape and topology of [13]macrodilactones. They were prepared in the same reaction pot because the diastereomeric
RCM precursors, an enantiomeric pair and a meso compound, could not be separated by
chromatography. The synthesis starts with diacylation of 1,3 propane-diol with two
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equivalence of 2-phenyl pentenoic acid and DCC and DMAP followed by ring closing
metathesis again by using Grubb’s 2nd generation catalyst. The two diastereomeric
macrocycles 1-25 and 1-26 were separated by column chromatography (Scheme 1-4).
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Scheme 1-4. Synthesis of C7, C12 diphenyl [13]-macrodilactones 1-24 and 1-26.

Both trans diastereomer 1-25 and cis diastereomer 1-26 were crystalline solids
that yielded to structural analysis from X-ray diffraction data. The structures of 1-25 and
1-26 revealed the interplay between the key stereocenters and their shapes. Specifically,
the relative (trans vs. cis) configuration of the phenyl groups at the α-stereogenic centers
dictated the shape adopted by each diastereomer and the configuration dictated the planar
chirality (Fig. 1-24). All four compounds differ in their topologies by virtue of either the
differences in their planar chirality or their shape.
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Fig. 1-24. Crystal structure of diastereomeric trans and cis [13]-macrodilactones, 1-25
and 1-26 (1-25 /trans = 7R,12R,pS and 7S,12S,pR; 1-26 /cis = 7S,12R,pR and 7R,12S,pS).
The trans isomer was a racemic mixture of 7R,12R,pS-1-25 and 7S,12S,pR-1-25
with its shape reminiscent of unsubstituted [13]-macrodilactones 1-19 and monosubstituted [13]-macrodilactones 1-20 and 1-22. In fact, the RMSD between the 1-20 and
7S,12S,pR-1-25 was only 0.0487. (Fig. 1-25a). This shape was adopted presumably
because the two phenyl substituents were oriented outside of the ring and thus minimized
transannular nonbonded interactions. The cis configured isomers of 1-26, on the other
hand, adopted a different shape (RMSD 0.49 between 1-20 and 7S,12S,pR-26) (Fig. 125b). Inspection of the top, or “triangle” views of 1-25 and 1-26 in Fig. 1-24 and 1-25
illustrates the difference. The non-ribbon shape of 1-26 is more compressed, or kinked,
relative to 1-25 and its molecular plane is also more twisted. While the diene precursor of
1-26 was meso, 1-26 itself is a mixture of enantiomers defined by the planar chirality

51

(pS or pR) introduced to the molecules by cyclization. The relative stereochemistry at C7
and C12 probably prevents formation of the ribbon shape because minimization of
transannular interactions in this case requires reconfiguration of the backbone and hence
a different shape.

Fig. 1-25. Overlays of 1-20 in cyan and (a) trans di-substituted 1-25 (b) cis disubstituted 1-26 in yellow.
We previously observed that other key stereogenic centers (C2 and C4) can work
constructively to reinforce the ribbon or against each other resulting in alternative shapes.
For the C2, C4 compounds, the trans series adopted the ribbon conformation akin to 1-19,
1-20, 1-22 and 1-25 whereas the cis series gave rise to a different macrocyclic shape that
was coincidentally distinct from the shape of 1-26. The ribbon conformation seems to be
of the lowest energy for these [13]-macrodilactones but, based on relative
stereochemistry, alternative shapes and consequently topologies are available. Together
the structural observations from this study suggest that shape and the topology of this
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family of [13]-macrodilactones can be fine-tuned based on specific combinations of
configuration on α-carbon stereogenic centers.

1.8.2 Synthesis of di-substituted [13]-macrodilactones with C2, C7 and C2, C12
substitution patterns
To explore some underlying general principles on the effect of combinations of
two stereogenic centers and substitution pattern on the planar chirality, shape and overall
topology of [13]-macrodilactones, we used the same synthetic route we have previously
reported to synthesize new di-substituted macrocycles with new substitution patterns
(Scheme 1-5). Compounds 1-27 and 1-28 have substituents at C2 and C12 while
compounds 1-29 and 1-30 have substituents at C2 and C7. 1-27 and 1-28 were
synthesized starting from 3-hydroxybutanol followed by acylation with 2-phenyl
pentenoic acid and DCC and DMAP. The resulting mono-acylated hydroxybutanol was
again acylated with, this time, pentenoic acid and DCC and DMAP. The last step is to
close the ring, again, using Grubbs’ second-generation caltalyst. The two diastereomers
1-27 and 1-28 (each a pair of enantiomers) were isolated using column chromatography.
The same route was used to synthesize the diastereomers 1-29 and 1-30 but instead of
using 2-phenyl pentenoic acid first followed by pentenoic acid, the sequential acylation
with DCC and DMAP was reversed where pentenoic acid was used first to acylate the 3hydoxybutanol followed by another acylation with 2-phenyl pentenoic acid (Scheme 1-5).
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Scheme 1-5. Synthesis of C2, C7 and C7, C12 di-substituted [13]-macrodilactones.

Similar to the C7, C12 (compounds 1-25 and 1-26) and C2, C4 (compounds 1-31
and 1-32) di-substituted [13]-macrodilactones, we isolated four stereosiomers with two
different shapes for C2, C7 and C2, C12 di-substituted macrocycles (Fig. 1-26 and 1-27).
The difference in planar chiralities, shape and overall topologies of all the di-substituted
[13]-macrodilcatones are evident in both the 2D maps and the crystal structures (Fig. 126 and 1-27).
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Fig. 1-26. Structural properties of di-substituted [13]-macrodilactones with various
substitution patterns and with pR planar chiralities as shown by the X-ray crystal
structures and 2D maps.
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Fig. 1-27. Structural properties of di-substituted [13]-macrodilactones with various
substitution patterns and with pS planar chiralities as shown by the X-ray crystal
structures and 2D maps.
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1.8.3 Effect of relative cis/trans configuration of substitutents on the topology of disubstituted 13-macrodilactones
With respect to the contribution of combinations of stereogenic centers to the shape
of the [13]-macrodilactone, we initially hypothesized that the relative (cis and

trans)

configuration dictates the shape of the macrocyle based on our observations on both C7,
C12 (Figs. 1-26a, 1-27a) and C2, C4 (Figs. 1-26c, 1-27c) macrocycles. We define the cis/trans
configuration in a similar manner to the designation of

cis/trans

configuration in

cyclohexane. The trans isomers adopted the ribbon shape and the cis adapted the alternate
shape. This trend held true for the C2, C12 macrocyle (Figs. 1-26c, 1-27c) but did not
apply to C2, C7 macrocyle where the cis configured macrocycle adopted the ribbon shape
and the trans adopted an alternate shape (Figs. 1-26d, 1-27d). Based on the crystal
structures of the new di-substituted macrocycles we obtained, it is clear that it is not the
relative

cis/trans

configuration that determines whether the di-substituted [13]-

macrodilactone will adopt th ribbon or the alternate shapes.

1.8.4 Effect of substitution pattern on the topology of di-substituted [13]macrodilactones
The alternative shape adopted by the di-substituted [13]-macrodilactone seemed to
depend on the substitution pattern. Macrocyles 1-26 and 1-28 with substitutions at C7,
C12 and C2, C12 respectively adopted a similar shape as shown by their crystal
structures and 2D maps (Figs. 1-26a, 1-27a and Figs. 1-26c, 1-27c). Macrocyles 1-26 and
1-28 have a five-atom alkene planar units instead of a four-atom planar units in the
ribbon/triangular shape. Formation of a five-atom planar unit forced the alkene plane to
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twist or deviate from the almost perpendicular orientation of the alkene plane (with
respect to the molecular plane) in the ribbon/triangular shape. This deviation is clearly
visualized through the positive migration of the alkene atoms in the 2D maps. Both 1-26
and 1-28 have a substituent at C12 suggesting that the configuration or the geometry at
C12 stereogenic center can greatly influence the shape of [13]-macrodilactones. More
specifically, the type of shape where a five-atom alkene planar unit was formed instead of
the typical four-atom alkene planar unit is probably controlled by the configuration at
C12.
Macrocycles 1-32 and 1-30 adopted yet another shape that is distinct from the
ribbon/triangular shape and that of 1-26 and 1-28 as evident from their crystal structures
and 2D maps (Figs. 1-26b, 1-27b and Figs. 1-26d, 1-27d). Pronounced difference can be
seen in the orientation of the two carbonyl groups. The C=O groups in 1-32 and 1-30 are
pointing in the same direction whereas in all the ribbon/triangular shape, the C=O groups
are pointing in opposite direction. This orientation of carbonyl groups in 1-32 and 1-30
probably forced the alkene plane to again deviate from the molecular plane. The
deviation from the molecular plane is also clearly visualized through the negative
migration of the alkene atoms (as opposed to the positive deviation seen for 1-26 and 128) in the 2D maps. Both 1-32 and 1-30 have a substituent at C2 suggesting that, similar
to C12, the configuration or the geometry at C2 stereogenic center can greatly influence
the shape of [13]-macrodilactone. More specifically, the type of shape where the two
carbonyls are pointing in the same direction is probably controlled by the configuration at
C2.
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1.8.5 Effect of the interplay between configurations at the stereogenic centers and
stereogenic plane on topology of di-substituted [13]-macrodilactones
Inspection of the crystal structures to explore some underlying general principle
that apply to all the di-substituted [13]-macrodilactones – with regard to the relationship
of configurations at stereogenic centers, planar chirality and shape - revealed that the
trend observed in mono-substituted macrocycles applies to the di-substituted [13]macrodilactones as well. For mono-substituted macrocycles, specific configuration at the
stereogenic center (either R or S) resulted in only one planar chirality (either pS or pR).
For C2 (and C4) streogenic center with methyl substituent, an R configuration should
have a pR planar chirality while an S configuration should have a pS planar chirality. For
the C7 (and C12) stereogenic center with phenyl substituent, it was the other way around.
The R configuration should have a pS planar chirality while the S configuration should
have a pR planar chirality (Table 2). As pointed out in the previous discussion, the
appearance of the lack of correspondence between the general correlation of point and
planar chirality for the C2-methyl and C7-phenyl mono-substituted macrocycles is due to
the assignment of functional group prioritization based on CIP R and S designations.
Specific geometry at the stereogenic center (point chirality) – driven by the preference for
a pseudo-equatorial position – do indeed control the planar chirality. Similarly for the disubstituted [13]-macrodilactones, if both configurations at the stereogenic centers agree
with the point to planar chirality correspondence (Table 1-2) observed for the monosubstituted [13]-macrodilactones – all of the substituents are in the pseudo-equatorial
positions i.e. Figs. 1-26a – 7S, 12S pR; 1-26b – 2R, 4R, pR; 1-26c – 2R, 12S, pR; and 126d – 2R, 7S, pR - the macrocycle adopts the most stable ‘ribbon’ shape. If on the other
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hand, one of the stereogenic centers does not agree with the point to planar chirality
correspondence – underlined stereogenic centers - (i.e. Fig. 1-26a - 7S, 12R, pR; 1-26b –
2R, 4S, pR; 1-26c – 2R, 12R, pR; and 1-26d – 2S, 7S, pR), the macrocycle is forced to
adopt a different or ‘alternate’ shape. For di-substituted [13]-macrodilactones, the proper
configurations at the two stereogenic centers (point chiralities) and the olefenic
stereogenic plane (planar chirality) is required to form the most stable conformation – the
‘ribbon shape’ - while if one of the substituents at the stereogenic centers has an incorrect
point to planar chirality correspondence, a different shape is adopted.

1.8.6 Origin of the control of [13]-macrodilactone shape by two stereogenic centers
We used a computational method once again to further explore the driving force
behind the preference for ‘alternate’ shape conferred by the incorrect point-to-planar
chirality correspondence in the stereogenic elements on the [13]-macrodilactones. Using
the C7, C12 di-substituted [13]-macrodilactone as an example, we used ground-state
energy minimization to look at the energy associated with the ‘ribbon’ shape (trans-7R,
12R, pS) vs. the ‘alternate’ shape (cis-7R, 12S, pS) (Fig. 1-28). The ‘alternate’ shape is
1.7 kcal/mol higher in energy than the ‘ribbon’ shape. Using the same combination of
configurations at stereogenic centers and at the stereogenic plane that gave rise to a nonribbon shape (7R, 12S, pS) and forcing it to adopt a ribbon shape instead led to a
conformation where one of the substituents is in pseudo-axial position (trans - 7R, 12R,
pS). The specific combination 7R, 12S, pS adopted an alternate shape because adopting a
ribbon shape is 2.4 kcal/mol higher in energy probably because of the transannular strain
induced by a substituent in a pseudo-axial position. Similar to the mono-substituted
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macrocycle, it looks like it’s still the preference for pseudo-equatorial position that
directs the type of shape adopted by the di-substituted [13]-macrodilactones.

Fig. 1-28. Ground state energy minimization of C7, C12 disubstituted [13]macrodilactones 1-25.
1.8.7 Conclusion: Rules of [13]-macrodilactone topology and its potential application
to other macrocyclic systems
Our systematic approach in investigating the interplay between the planar units
and the stereogenic elements (point chirality and planar chirality) to the overall structure
of [13]-macrodilactones has provided some valuable insights that we thought would be
helpful in synthesizing macrocyles with designed structural properties. Although our
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observations are primarily based on X-ray crystallography data and some computational
methods and are thus bound by the limitations inherent to these types of analyses, we
believe that the fundamental information we learned from the [13]-macrodilactone
systems has some value. Below, we outlined the lessons we learned from this effort and
discuss how it might be applicable to other ring systems with similar chemical
composition.

1) Unsubstituted [13]-macrodilactone adopts a single shape - a ‘ribbon’ shape when
viewed from the side or a ‘triangular’ shape when viewed from the top of the
molecular plane. This shape is rigidified by planar units alone. It exists as a pair of
enantiomers brought about by stereogenic alkene plane.
For macrocycels that contain rigidifying planar units (macrolides, macrolactams,
cyclic peptides or macrocycles with embedded alkene), there might be a preferred
stable shape that is controlled by planar units alone. E-alkene containing macrocycles
(without substituents) will most likely exist as a pair of planar enantiomers.

2) There is a specific point-to-planar chirality correspondence when one stereogenic
center is incorporated in [13]-macrodilactone regardless of the location and type of
substituent. This means that a specific geometrical arrangement at a stereogenic
center confers selectivity towards a specific planar chirality. If the substituent is
considered to have the lowest priority based on CI specifications for assigning the
configurations at stereogenic centers, the point-to-planar chirality correspondence is
R to pR and S to pS. This selectivity is driven by the preference of the substituents to
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be oriented away from the ring or in pseudo-equatorial position. Regardless of type
and location of stereogenic center, [13]-macrodilactone with one substituent adopted
the same ribbon shape.
This observation implies that for E-alkene containing macrocyles,
synthesizing macrocyles with a specific planar chirality (either pS or pR) is possible
by incorporating a stereogenic center around the ring with a specific configuration
(either R or S). For macrocycles that contain rigidifying planar units (macrolides,
macrolactams, cyclic peptides or macrocycles with embedded alkene), changing the
shape of macrocycles might not be possible by just incorporating one stereogenic
center around the ring.

3) All the di-substituted [13]-macrodilactone gave four different streoisomers with two
different shapes (ribbon and various alternate shapes). A proper configuration controlled by the preference for pseudo-equatorial position - at both stereogenic
centers and stereogenic plane is required to get the most stable ribbon shape.
However, if one configuration at either setreogenic centers or the stereogenic plane
do not match, an alternate shape is adopted which varies depending on the
substitution pattern.
In designing macrocycles with different shapes, at least two stereogenic
centers might be needed to be incorporated in the ring. The most stable shape defined
by the planar units alone is accessible only if all the substituents around the ring are in
pseudo-equatorial position. If one of the substituents is in pseudo-axial position, an
‘alternate’ shape will be adopted. Moreover, various ‘alternate’ shapes can be
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accessed depending on the substitution pattern. This observation we believe, will be
very helpful for generating macrocyclic compound libraries with varied skeletons and
for medicical chemists who are trying to optimze the biological and pharmacological
profiles of bioactive macrocyles.
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1.9 Experimental Section
Experimental procedures and characterization of compounds in Chapter 1

General
Reactions were monitored using TLC. UV light, p-anisaldehyde, potassium
permanganate (KMnO4) or ceric ammonium molybdate (CAM) solutions were used for
visualization. Chromatography was performed on silica gel and solvent systems used
were based on the Rf values. 1H NMR spectra (400 MHz ) were referenced to CDCl3 (δH
7.27 ppm) and 13CNMR spectra (100 MHz) were referenced to CDCl3 (δC 77.23 ppm).

Sequential Acylations
Method A:
Dicyclohexylcarbodiimide

(DCC)

(1.09

mmol)

and

N,N-dimethylaminopyridine

(DMAP) (0.3 mmol) in DCM (7 mL) were stirred at 0 °C. 4-pentenoic acid (1 mmol) was
added and the mixture was stirred at the same temperature for 30 minutes until a white
suspension was observed in the flask. 1,3-propanediol (1 mmol) in DCM (3 mL) was then
added to the reaction mixture and stirred overnight at room temperature. The mixture was
filtered through a celite and solvent was removed from the filtrate under reduced pressure.
The crude residue was purified by silica gel column chromatography (3:1 Hex:EtOAc) to
give the monoacylated product.
Method B:
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DCC (1.09 mmol) and DMAP (0.3 mmol) were added in DCM (40 mL) and cooled to
0°C. The acid of choice (1 mmol) was added to the solution and stirred at the same
temperature for 30 minutes. The monoacylated product (1 mmol) from the first acylation
was then added to the mixture and stirred overnight at room temperature. The reaction
mixture was filtered through celite and the solvent of the filtrate was removed under
reduced pressure. Crude residue was purified by silica gel column chromatography to get
the diene.

One-pot acylation
In a round bottom flask, DCC (0.23 g, 1.09 mmol) and DMAP (.037 g, 0.300 mmol) were
dissolved in DCM (40mL), and the solution was cooled to 0°C. The acid of choice (1.00
mmol) was added and stirred at the same temperature for 30 minutes. Either 1,3butanediol or 1,3-propanediol (0.500 mmol) in DCM (10 mL) was then added to the
mixture and stirred overnight at room temperature. The mixture was then filtered through
celite. The solvent of the filtrate was removed under reduced pressure and the residue
was purified by silica gel column chromatography to get the diene.

Ring Closing Metathesis
Grubbs’ second-generation catalyst (0.050 mmol) was added to a solution of the diene (1
mmol) in toluene (100 mL). The mixture was heated to reflux at 110 °C overnight. The
toluene was removed under reduced pressure and the crude product was purified by
column chromatography.
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DMDO Epoxidation (Lee, D.; Sello, J. K.; Schreiber S. L. J. Am. Chem. Soc. 1999, 121,
10648-10649)
Excess amount of NaHCO3 (0.450 g, 0.94 mmol) and Oxone (0.450 g, 0.19 mmol) was
added to a solution of

[13]-macrodilactone (racemic or chiral) (75 mg) in

acetone:H2O:DCM (1:1:1, 15 mL) at 0 °C. The resulting heterogeneous mixture was
stirred for 3 h at 0 °C and extracted with DCM. The epoxide was purified using column
chromatography.
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Characterization
O

O

HO

3-hydroxypropyl 4-pentenoate. The synthesis of this compound followed the general
monoacylation procedure (Method A) to give 3-hydroxypropyl 4-pentenoate in 52% yield
as a colorless oil (1.0 mmol scale). Rf 0.2 (30% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz.
δ 5.82 (ddd, 1H, J= 10.4, 6.3, 6.3, 6.3 Hz), 5.08 (dd, 1H, J = 16.6, 16.6, 0 Hz), 5.02 (dd,
1H, J= 10.2, 10.2, 0 Hz), 4.25 (t, 2H, J = 6.1 Hz), 3.69 (m 2H), 2.80 (s, 1H), 2.41 (m, 4H),
1.88 (qn, 2H, J = 6.1 Hz); 13C NMR (CDCl3) 100 MHz δ 173.6, 136.6, 115.6, 61.5, 59.0,
33.6, 31.7, 28.9; TOF HRMS (DART) m/z calcd for C9H16O3 (M+H)+ 173.1099, found
173.1191

O

O

O
O

1-18. The synthesis of this compound can follow either the general procedure for
synthesizing dienes (Method A and then Method B) or a one-pot acylation. The general
route for dienes gave a better yield of (96%) in 26.0 mmol scale as colorless oil. Rf 0.58
(20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3) δ 5.83 (dddd/dq, 2H, J= 23.4, 6.4, 6.4,
6.4), 5.04 (ddd, 4H, J= 24.7, 17.1, 1.3), 4.17 (ddd, 4H, J= 6.42, 6.42, 0), 2.42 (m, 8H),
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1.98 (dddd/tt, 2H, J= 6.3, 6.3, 6.3, 6.3);

13

C NMR (100 MHz, CDCl3) δ 173.2, 136.8,

115.8, 61.2, 33.7, 29.1, 28.2; TOF HRMS (DART) m/z calcd for C13H20O4 (M+H)+
241.1439, found 241.1425

O

O

O
O

1-20. Followed the general RCM method to give the product in 54% yield and as a white
crystalline solid (2.08 mmol scale). m.p. 61.2 – 61.7 °C; Rf 0.34 (20% EtOAc:Hex);
1

HNMR (400 MHz, CDCl3) δ 5.44 (m, 2H), 4.18 (ddd/dt, 4H, J= 5.7, 5.7, 0), 2.33 (m,

8H), 2.02 (dddd/tt, 2H, J= 6.1, 6.1, 6.1, 6.1); 13C NMR (100 MHz, CDCl3) δ 173.9, 130.0,
60.7, 34.4, 28.7, 26.1; TOF HRMS (DART) m/z calcd for C11H16O4 (M+H)+ 213.1127,
found 213.1158

O
O

O
O
Ph

rac-1-21. The synthesis of this compound followed the general method of dienes through
monoacylation (Method B) in 50% yield and as a clear yellowish oil (0.63 mmol). Rf 0.6
(20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33 (m, 4H), 7.28 (m, 1H), 5.83 (m,
1H), 5.74 (dddd/ddt, 1H, J= 17.0, 10.3, 6.7, 6.7), 5.08 (m, 2H), 5.01 (dd, 2H, J= 10.4,
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5.0), 4.16 (ddd, 2H, J= 17.5, 11.34, 6.3), 4.08 (m, 2H), 3.66 (dd, 1H, J= 8.5, 7.1), 2.85
(ddd, 1H, J= 14.8, 8.2, 8.2), 2.54 (ddd, 1H, J= 13.8, 6.8, 6.8), 2.39 (ddd, 4H, J= 15.5,
11.35, 4.17), 1.93 (dddd/dq, 2H, J= 6.48, 6.48, 6.48, 6.48); 13C NMR (CDCl3) 100 MHz
δ 173.5, 173.1, 138.7, 136.8, 135.4, 128.9, 128.1, 127.6, 117.3, 115.8, 61.5, 61.0, 51.7,
37.7, 33.7, 29.1, 28.1; TOF HRMS (DART)m/z calcd for C19H24O4 (M+H)+ 317.1753,
found 317.1732.
O
O

O
O
Ph

S-1-21. Followed the general method of dienes through monoacylation (method A and
then method B) in 75% yield as a yellowish oil (0.79 mmol). Rf 0.6 (20% EtOAc:Hex);
[a]D +257.4° (c 1.0, CH2Cl2);1HNMR (CDCl3) 400 MHz. δ 7.30 (m, 5H), 5.80 (m, 2H),
5.08 (m, 2H), 5.02 (dd, 2H, J=10.3, 4.9), 4.16 (ddd, 2H, J= 17.57, 11.09, 6.31), 4.07 (m,
2H), 3.66(dd, 1H, J= 8.5, 7.0), 2.84 (ddd, 1H, J= 15.01, 8.07, 8.07), 2.54 (ddd, 1H, J=
13.64, 6.74, 6.74), 2.38 (ddd, 4H, J= 14.71, 11.34, 4.35), 1.92 (dddd/dq, 2H, J= 6.37,
6.37, 6.37, 6.37); 13C NMR (CDCl3) 100 MHz δ 173.5, 173.1, 138.7, 136.8, 135.4, 128.8,
128.1, 127.6, 117.2, 115.7, 61.5, 61.0, 51.7, 37.6, 33.7, 29.0, 28.1; TOF HRMS (ESI)
m/z calcd for C19H24O4 (M+Na)+ 339.1572, found 339.1556.
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O
O

O
O
Ph

rac-1-22. Followed the general RCM method to give the product in 54% yield and as a
white crystalline solid. m.p. 78-79 °C; Rf 0.4 (20% EtOAc:Hex); 1HNMR (CDCl3) 400
MHz. δ 7.37 (d, 2H, J= 7.1), 7.31 (dd, 2H, J= 7.1, 7.1), 7.26 (dd, 1H, J= 3.1, 3.1), 5.55
(m, 2H), 4.54 (m, 1H), 4.44 (m, 1H), 4.01 (ddd/dt, 1H, J= 8.2, 4.1, 4.1), 3.83 (ddd/dt, 1H,
J= 8.2, 4.1, 4.1), 3.60 (dd, 1H, J= 12.6, 2.7), 2.77 (ddd/dt, 1H, J= 12.9, 12.0, 8.1), 2.35
(m, 5H), 2.03 (m, 2H); 13C NMR (CDCl3) 100 MHz δ 174.2, 173.9, 139.1, 131.1, 129.1,
128.9, 127.9, 127.6, 60.6, 60.4, 52.1, 37.9, 34.3, 28.8, 26.0; anal. for C17H20O4, C 70.78,
H 6.96, O 22.26, found C 70.86, H 6.96.

O
O

O
O
Ph

7S,pR-1-22. Followed the general method of RCM in 25% yield (scale) as a white solid.
m.p. 72-74 °C; [a]D +2.6° (c 1.0, CH2Cl2); Rf 0.4 (20% EtOAc:Hex); 1HNMR (CDCl3)
400 MHz. δ 7.39 (d, 2H, J= 7.2), 7.23 (dd, 2H, J= 7.2, 7.2), 7.26 (m, 1H), 5.56 (m, 2H),
4.54 (m, 1H), 4.46 (m, 1H), 4.04 (ddd/dt, 1H, J= 8.4, 4.0, 4.0), 3.86 (ddd/dt, 1H, J= 8.4,
4.0, 4.0), 3.62 (dd, 1H, J= 12.6, 2.9), 2.79 (ddd/dt, 1H, J= 12.9, 12.9, 8.2), 2.37 (m, 5H),
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2.05 (m, 2H); ); 13C NMR (CDCl3) 100 MHz δ 174.1, 173.9, 139.0, 131.0, 129.0, 128.8,
127.9, 127.6, 60.6, 60.4, 52.0, 37.9, 34.3, 28.7, 26.0; TOF HRMS (ESI) m/z calcd for
C17H20O4 (M+Na)+ 311.1259, found 311.1253.

O
O

O

O

O
Ph

rac-1-23. Compound rac-1-22 was epoxidized using a procedure for in situ generation of
DMDO as described to give rac-1-23 in 64% yield (0.26 mmol) and as a white solid. m.p.
100-102 °C; Rf 0.2 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.30 (m, 5H), 4.82
(m, 2H), 3.91 (ddd/dt, 1H, J= 8.1, 3.7, 3.7), 3.72 (m, 2H), 2.87 (ddd, 2H, J= 8.8, 8.8, 2.6),
2.47 (dd, 2H, J= 8.24, 5.04), 2.24 (m, 2H), 2.03 (m, 3H), 1.60 (m, 1H);

13

C NMR

(CDCl3) 100 MHz δ 173.4, 172.9, 139.1, 129.0, 127.7, 127.6, 60.2, 59.5, 58.5, 57.6, 47.8,
36.7, 29.6, 26.9, 26.3; TOF HRMS (ESI) m/z calcd for C17H20O5 (M+Na)+ 327.1208, found
327.1206.

O
O

H

O

H O
O
Ph
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7S,pR-1-23. Compound 7S,pR-1-22 was epoxidized using a procedure for in situ
generation of DMDO as described to give 7S,pR-1-23 in 67% yield and as a white solid
(0.25 mmol). mp 114-118 °C; [a]D +120.3° (c 1.0, CH2Cl2); Rf 0.2 (20% EtOAc:Hex);
1

HNMR (CDCl3) 400 MHz. δ 7.29 (m, 5H), 4.83 (m, 2H), 3.92 (ddd/dt, 1 H, J= 8.2, 4.3,

4.3), 3.73 (m, 2H), 2.87 (ddd, 2H, J= 8.8, 8.8, 2.6), 2.47 (dd, 2H, J= 8.2, 5.3), 2.25 (m,
2H), 2.06 (m, 2H), 2.00 (ddd/dt, 1H, J= 12.9, 9.6, 9.6), 1.61 (m, 1H); 13C NMR (CDCl3)
100 MHz δ 173.4, 172.9, 139.1, 129.1, 127.7, 127.6, 60.2, 59.5, 58.5, 57.6, 47.8, 36.7,
29.6, 26.9, 26.3; TOF HRMS (ESI) m/z calcd for C17H20O5 (M+Na)+ 327.1208, found
+

327.1216.

O
O
Ph
O
O
Ph

1-24. Followed the general procedure of diene through diacylation in 46% yield and clear
yellowish oil (2.55 mmol). Rf 0.8 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.22
(m, 10H), 5.63 (dddd/dt, 2H, J= 17.3, 10.3, 7.0, 7.0), 5.00 (dd, 2H, J= 17.1, 1.3), 4.92 (dd,
2H, J= 10.2, 0), 3.96 (m, 4H), 3.54 (dd, 2H, J= 7.9, 7.9), 2.73 (ddd, 2H, J= 14.58, 8.05,
8.05), 2.43 (ddd, 2H, J= 13.93, 6.75, 6.75), 1.77 (dddd/tt, 2H, J= 6.13, 6.13, 6.13, 6.13);
13

C NMR (CDCl3) 100 MHz δ 173.5, 138.7, 135.4, 128.9, 128.1, 127.6, 117.3, 61.3, 51.7,

37.7, 28.1; TOF HRMS (ESI) m/z calcd for C25H28O4 (M+Na)+ 365.1753, found 365.1749.
+
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O
O
Ph
O
O
Ph

1-25. Followed the general method of RCM in 47% yield (0.45 mmol) and as a white
solid. m.p. 172-174 °C; Rf 0.56 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33
(m, 10H), 5.64 (ddd/dt, 2H, J= 3.67, 3.67, 0), 4.67 (m, 2H), 3.80 (ddd/dt, 2H, J= 7.09,
3.17, 3.17), 3.62 (dd, 2H, J= 12.50, 2.14), 2.82 (m, 2H), 2.28 (dd, 2H, J= 12.62, 0), 2.03
(m, 2H);

13

C NMR (CDCl3) 100 MHz δ 174.1, 139.0, 130.3, 128.9, 127.8, 127.6, 59.7,

51.8, 38.1, 25.5; TOF HRMS (DART) m/z calcd for C23H24O4 (M+H)+ 365.1753, found
365.1749

O
O
Ph
O
O
Ph

1-26. Followed the general method of RCM in 20% yield and as a white solid. m.p. 147156 °C; Rf 0.44 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz. δ 7.33 (m, 10 H), 5.74
(ddd, 2H, J= 2.84, 2.84, 0), 4.41 (ddd, 2H, J= 11.37, 5.71, 5.71), 4.09 (ddd, 2H, J= 10.93,
5.15, 5.15), 3.75 (ddd, 2H, J= 12.17, 3.31, 0), 2.78 (m, 2H), 2.40 (dd, 2H, J= 13.57, 0),
2.08 (dddd/dq, 2H, J= 5.20, 5.20, 5.20, 5.20); 13C NMR (CDCl3) 100 MHz δ 174.1, 139.1,
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129.7, 128.9, 128.1, 127.7, 63.1, 52.4, 36.9, 27.3; TOF HRMS (DART) m/z calcd for
C23H24O4 (M+H)+ 365.1753, found 365.1748.

O

O

O
O
Ph

diacylated diene precursor of 1-27 and 1-28. Followed the general method of dienes
through monoacylation of 1,3 butanediol first with pentenoic acid to get the
monoacylated 1,3 butanediol (method A) and then method B using 2-phenyl pentenoic
acid in 62% yield as a yellowish oil (0.8 mmol). Rf 0.8 (20% EtOAc:Hex); 1HNMR (400
MHz, CDCl3) δ (m, 5H), 5.77 (m, 2H), 5.03 (m, 5H), 4.09 (m, 1H), 3.99 (ddd, 1H, J=
11.4, 6.1, 6.1), 3.83 (ddd, 1H, J= 13.9, 7.8, 6.1), 3.63 (m, 1H), 2.83 (m, 1H), 2.54 (m, 1
H), 2.39 (m, 1H), 2.34, (m, 2H), 1.83 (m, 2H), 1.25 (m, 2H), 1.15 (m, 3H);

13

C NMR

(100 MHz, CDCl3) δ 173.1, 138.9, 136.9, 135.5, 128.9, 128.0, 127.6, 117.1, 115.7, 68.5,
60.7, 51.8, 37.6, 34.9, 33.6, 29.0, 20.3, 20.0; TOF HRMS (DART) m/z calcd for
C23H26O4 (M+H)+ 331.1909, found 331.1921.

O

O

O
O
Ph
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1-27. Obtained using the general RCM procedure in 21.2% yield (0.5 mmol) and as a
white solid. m.p. 85.0 – 85.7 °C; Rf 0.48 (20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3)
δ 7.28 (m, 5H), 5.52 (m, 2H), 5.09 (ddd, 1H, J= 10.6, 6.1, 3.8), 4.34 (ddd, 1H, J= 12.1,
12.1, 3.6), 3.94 (ddd, 1H, J= 11.2, 5.2, 2.2), 3.54 (ddd, 1H, J= 12.6, 2.5, 0), 2.79 (ddd, 1H,
J= 13.0, 13.0, 9.3), 2.30 (m, 5H), 2.01 (m, 1H), 1.78 (m, 1H), 1.16 (dd, 3H, J= 6.24, 0);
13

C NMR (100 MHz, CDCl3) δ 174.1, 173.3, 139.1, 131.7, 129.12, 128.9, 127.6, 127.5,

67.3, 60.5, 52.2, 37.6, 34.5, 33.5, 29.2, 20.5; TOF HRMS (DART) m/z calcd for
C18H22O4 (M+H)+ 303.1596, found 303.1005

O

O

O
O
Ph

1-28. Obtained using the general RCM procedure in 4.6% yield (0.5 mmol) and as a
white solid. m.p. 96.3 – 96.9 °C; Rf 0.42 (20% EtOAc:Hex); 1HNMR (400 MHz, CDCl3)
δ 7.30 (m, 5H), 5.60 (m, 2H), 5.12 (ddd, 1H, J= 9.9, 6.3, 3.7), 4.16 (m, 1H), 4.07 (m, 1H),
3.83 (ddd, 1H, J= 11.7, 3.6, 0), 2.70 (ddd, 1H, J= 15.7, 11.7, 4.3), 2.39 (m, 5H), 1.96
(dddd, 2H, J= 8.9, 8.9, 4.2, 4.2), 1.20 (dd, 3H, J= 6.4, 0); 13C NMR (100 MHz, CDCl3) δ
174.2, 172.7, 139.4, 129.5, 128.9, 128.6, 128.0, 127.5, 69.4, 61.1, 52.2, 35.4, 34.0, 29.7,
20.8; TOF HRMS (DART) m/z calcd for C18H22O4 (M+H)+ 303.1596, found 303.1606
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O
Ph

O

HO

3-hydroxybutyl 2-phenyl-4-pentenoate. The synthesis of this compound followed the
general monoacylation procedure (Method A) to give 3-hydroxybutyl 2-phenyl-4pentenoate in 44% yield as a colorless oil (2.0 mmol scale). Rf 0.2 (30% EtOAc:Hex);
1

HNMR (CDCl3) 400 MHz δ 7.30 (m, 5H), 5.74 (ddt/dddd, 1H, J = 17.2, 10.5, 6.9, 6.9),

5.09 (dd, 1H, J = 17.2, 0.0), 5.03 (dd, 1H, J = 10.3, 0), 4.34 (ddt/ dddd, 1H, J = 11.4, 8.4,
5.0, 5.0), 4.13 (ddt/ dddd, 1H, J = 11.2, 7.7, 5.6, 5.6), 3.74 (m, 1H), 3.66 (dd, 1H, J = 8.7,
6.9), 2.85 (ddd, 1H, J = 15.7, 8.5, 7.6), 2.54 (m, 1H), 2.19 (m, 1H), 1.71 (m, 2H), 1.16
(dd, 3H, J= 6.0, 4.0);

13

C NMR (CDCl3) 100 MHz δ 174.0, 135.4, 128.9, 128.1, 127.6,

117.3, 65.1, 62.4, 62.3, 51.8, 38.2, 37.6, 23.6; TOF HRMS (DART) m/z calcd for
C15H20O3 (M+H)+ 249.1491, found 249.1502

O
Ph

O

O
O

diacylated diene precursor of 1-29 and 1-30. Followed the general method of dienes
through monoacylation of 1,3 butanediol first with pentenoic acid to get the
monoacylated 1,3 butanediol (method A) and then method B using 2-phenyl pentenoic
acid in 62% yield as a yellowish oil (0.8 mmol). Rf 0.6 (20% EtOAc:Hex); 1HNMR
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(CDCl3) 400 MHz δ 7.26 (m, 5H), 5.72 (m, 2H), 5.00 (m, 5H), 4.09 (m, 2H), 3.62 (dd,
1H, J= 8.3, 7.1), 2.82 (ddd, 1H, J = 14.8, 7.6, 7.6), 2.51 (ddd, 1H, J =13.9, 6.7, 6.7), 2.35
(dd, 2H, J = 2.5, 0), 2.33 (dd, 2H, J = 2.6, 0.0), 2.20 (m, 2H), 1.17 (dd, 3H, J = 8.5, 6.5);
13

C NMR (CDCl3) 100 MHz δ 173.4, 172.4, 138.6, 136.7, 135.3, 128.7, 128.0, 127.4,

117.1, 115.6, 67.9, 61.3, 51.6, 37.5, 34.8, 33.8, 29.0, 20.1; TOF HRMS (DART) m/z
calcd for C20H26O4 (M+H)+ 331.1409, found 331.1920.

O
Ph

O

O
O

1-29. Obtained using the general RCM procedure in 13% yield (0.5 scale) and as a white
solid. m.p. 112-113 °C; Rf 0.52 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz δ 7.30 (m,
5H), 5.52 (ddd/dt, 2H), J = 8.8, 4.8, 4.8), 5.12 (m, 1H), 4.39 (ddd, 1H, J= 14.9, 11.1, 3.6),
3.76 (ddd, 1H, J = 11.1, 5.7, 1.4), 3.54 (ddd, 1H, J= 12.5, 2.6, 0.0), 2.74 (ddd, 1H, J =
13.0, 13.0, 9.1), 2.41 (m, 2H), 2.27 (m, 3H), 2.02 (m, 1H), 1.75 (m, 1H), 1.29 (dd, 3H, J
= 6.2, 0); 13C NMR (CDCl3) 100 MHz δ 174.4, 172.9, 139.0, 130.9, 129.7, 128.8, 127.9,
127.6, 66.8, 60.5, 52.1, 38.3, 34.3, 33.5, 28.2, 20.7; TOF HRMS (DART) m/z calcd for
C18H22O4 (M+H)+ 303.1596, found 303.1594

O
Ph

O

O
O
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1-30. Obtained using the general RCM procedure in 17% yield (0.5 mmol) and as a white
solid. m.p. 75 °C; Rf 0.47 (20% EtOAc:Hex); 1HNMR (CDCl3) 400 MHz δ 7.31(m, 5H),
5.65 (ddd/dt, 2H, J = 5.9, 5.9, 5.9), 5.13 (m, 1H), 4.33 (ddd, 1H, J = 11.6, 6.8, 3.4), 3.70
(ddd, 1H, J = 0, 3.7, 11.6), 2.68(m, 1H), 2.41 (m, 4H), 2.26 (m, 1H), 1.96 (m, 2H), 1.28
(dd, 3H, J = 6.2, 0.0); 13C NMR (CDCl3) 100 MHz δ 174.1, 173.4, 139.1, 130.9, 129.2,
128.9, 128.3, 127.5, 70.1, 62.7, 52.7, 36.7, 35.0, 34.3, 27.5, 20.9; TOF HRMS (DART)
m/z calcd for C18H22O4 (M+H)+ 303.1596, found 303.1637

X-ray Crystallography Data

Procedure for determination of RMSDs
The root mean square deviations (RMSDs) were produced with the structure overlay
feature of the Mercury software package. Pairs of atoms were selected to calculate the
square root of the mean square differences between atomic coordinates. Our approach
focused on the 13 atoms of the macrocycle in compound 1. These coordinates were
mapped onto the corresponding atom positions of compounds 4, 6, and 7. All of the
compounds reported here crystallized as racemic mixtures. The coordinates were
carefully inspected to insure the average RMSD between two sets of coordinates reflected
corresponding conformations in the alkene and ester functional groups.
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X-ray Crystallography Data

Procedure for determination of RMSDs
The root mean square deviations (RMSDs) were produced with the structure overlay
feature of the Mercury software package. Pairs of atoms were selected to calculate the
square root of the mean square differences between atomic coordinates. Our approach
focused on the 13 atoms of the macrocycle in compound 1-20. These coordinates were
mapped onto the corresponding atom positions of compounds 1-22, 1-25, and 1-26. All of
the compounds reported here crystallized as racemic mixtures. The coordinates were
carefully inspected to insure the average RMSD between two sets of coordinates reflected
corresponding conformations in the alkene and ester functional groups.
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Fig. 1-29 A thermal ellipsoid plot of 1-19 (spider-15025) at a 50% probability level. The
full numbering scheme is shown. Hydrogen atoms are depicted as spheres.
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Table 1-3. Crystal data and structure refinement for 1-19 (spider-15025).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Crystal color and habit
Diffractometer
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Observed reflections (I > 2σ(I))
Completeness to θ = 25.242°
Absorption correction
Max. and min. transmission
Solution method
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices (all data)
Largest diff. peak and hole

spider-15025
C11H16O4
212.24
93(2) K
0.71075 Å
Monoclinic
P 21/c
a = 12.9215(9) Å
α = 90°.
b = 9.3726(2) Å
β = 91.858(6)°.
c = 8.9925(2) Å
γ = 90°.
3
1088.49(8) Å
4
1.295 Mg/m3
0.098 mm-1
456
0.410 x 0.380 x 0.260 mm3
Colorless Block
Rigaku R-AXIS RAPID imaging plate
3.140 to 27.474°.
-16 ≤ h ≤ 16, -12 ≤ k ≤ 12, -11 ≤ l ≤ 11
42983
2492 [R(int) = 0.0300]
2255
99.9 %
Semi-empirical from equivalents
1.000 and 0.945
SHELXS-2013 (Sheldrick, 2013)
SHELXL-2014/7 (Sheldrick, 2014)
2492 / 0 / 136
1.071
R1 = 0.0320, wR2 = 0.0807
R1 = 0.0349, wR2 = 0.0823
0.311 and -0.174 e.Å-3
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Fig. 1-30 A thermal ellipsoid plot of rac-1-22 (spider-15025) at a 50% probability level.
The full numbering scheme is shown. Hydrogen atoms are depicted as spheres.
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Table 1-4. Crystal data and structure refinement for compound 1-22.
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal color
Crystal size
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to θ = 67.687°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I) = 4987 data]
R indices (all data)
Largest diff. peak and hole

compound 4
C17H20O4
288.33
93(2) K
1.54187 Å
Triclinic
P1
a = 5.51640(10) Å
b = 11.8803(3) Å
c = 23.3669(16) Å
1508.23(12) Å3
4
1.270 Mg/m3
0.731 mm-1

α = 94.989(7)°
β = 90.739(6)°
g = 98.520(7)°

616
Colorless
0.200 x 0.200 x 0.050 mm3
1.899 to 68.240°
-6 ≤ h ≤ 6, -14 ≤ k ≤ 14, -28 ≤ l ≤ 28
54047
5407 [R(int) = 0.0459]
98.3 %
Semi-empirical from equivalents
0.964 and 0.802
Full-matrix least-squares on F2
5407 / 0 / 379
1.054
R1 = 0.0391, wR2 = 0.0948
R1 = 0.0421, wR2 = 0.0973
0.446 and -0.216 e.Å-3
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Figure 1-31. A thermal ellipsoid plot of 1-25 at a 50% probability level. The full
numbering scheme is shown. Hydrogen atoms are depicted as spheres.
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Table 1-5. Crystal data and structure refinement for compound 1-25.
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal color
Crystal size
Theta range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to theta = 25.242°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2

compound 6
C23H24O4
364.42
150(2) K
0.71075 Å
Triclinic
P1
a = 5.5848(4) Å
b = 11.7915(8) Å
c = 15.6064(11) Å
952.16(12) Å3

α = 69.615(5)°.
β = 84.229(6)°.
g = 81.837(6)°.

2
1.271 Mg/m3
0.086 mm-1
388
Colorless
0.220 x 0.210 x 0.190 mm3
3.494 to 27.468°
-7 ≤ h ≤ 7, -15 ≤ k ≤ 15, -20 ≤ l ≤ 20
16756
4345 [R(int) = 0.0758]
99.8 %
Semi-empirical from equivalents
0.984 and 0.795
Full-matrix least-squares on F2

4345 / 0 / 245
1.092
Final R indices [I>2sigma(I) = 2226 data] R1 = 0.0510, wR2 = 0.1119
R indices (all data, ? Å)
R1 = 0.1232, wR2 = 0.1695
Extinction coefficient
0.033(5)
Largest diff. peak and hole
0.294 and -0.298 e.Å-3
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Figure 1-32. A thermal ellipsoid plot of 1-26 at a 50% probability level. The full
numbering scheme is shown. Hydrogen atoms are depicted as spheres.
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Table 1-6. Crystal data and structure refinement for compound 1-26.
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal color
Crystal size
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to θ = 66.499 °
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I) = 3006 data]
R indices (all data)
Largest diff. peak and hole

compound 7
C23H24O4
364.42
93(2) K
1.54187 Å
Triclinic
P1
a = 5.59160(10) Å
α = 70.326(5)°.
b = 11.9281(2) Å
β = 80.097(6)°.
c = 15.3677(11) Å
g = 79.031(6)°.
3
941.04(8) Å
2
1.286 Mg/m3
0.701 mm-1
388
Colorless
0.270 x 0.140 x 0.050 mm3
3.075 to 66.499°
-6 ≤ h ≤ 6, -14 ≤ k ≤ 14, -18 ≤ l ≤ 18
28626
3254 [R(int) = 0.0430]
97.8 %
Semi-empirical from equivalents
0.966 and 0.850
Full-matrix least-squares on F2
3254 / 0 / 244
1.073
R1 = 0.0294, wR2 = 0.0735
R1 = 0.0317, wR2 = 0.0749
0.208 and -0.153 e.Å-3

88

Figure 1-33. A thermal ellipsoid plot of 1-27 (spider_13084) at a 50% probability level.
The hydrogen atoms are shown as spheres.
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Table 1-7. Crystal data and structure refinement for compound 1-27 (spider_13084).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal color
Crystal size
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to θ = 25.242°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I) = 2883 data]
R indices (all data)
Largest diff. peak and hole

spider_13084
C18H22O4
302.35
150(2) K
0.71075 Å
Orthorhombic
Pbca
a = 8.9681(3) Å
b = 9.8245(3) Å
c = 36.663(3) Å
3230.3(3) Å3

a = 90°
b = 90°
g = 90°

8
1.243 Mg/m3
0.087 mm-1
1296
Colorless
0.220 x 0.200 x 0.190 mm3
3.125 to 27.483°
-11 ≤ h ≤ 11, -12 ≤ k ≤ 12, -47 ≤ l ≤ 47
98785
3708 [R(int) = 0.0762]
99.9 %
Semi-empirical from equivalents
0.984 and 0.849
Full-matrix least-squares on F2
3708 / 0 / 290
1.057
R1 = 0.0483, wR2 = 0.1037
R1 = 0.0674, wR2 = 0.1120
0.149 and -0.190 e.Å-3
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Figure 1-34. A thermal ellipsoid plot of 1-28 (007-15017) at a 50% probability level.
The hydrogen atoms are shown as spheres. The chirality of atom C2 is R; C12 is R.
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Table 1-8. Crystal data and structure refinement for 1-28 (007-15017).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Crystal color and habit
Diffractometer
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Observed reflections (I > 2σ(I))
Completeness to θ = 67.679°
Absorption correction
Max. and min. transmission
Solution method
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices (all data)
Largest diff. peak and hole

007-15017
C18H22O4
302.35
93(2) K
1.54178 Å
Monoclinic
C 2/c
a = 17.6902(12) Å
α = 90°.
b = 5.6442(4) Å
β = 103.867(2)°.
c = 32.347(2) Å
γ = 90°.
3
3135.6(4) Å
8
1.281 Mg/m3
0.727 mm-1
1296
0.200 x 0.200 x 0.090 mm3
Colorless Prism
Rigaku Saturn 944+ CCD
2.814 to 67.878°.
-20 ≤ h ≤ 21, -6 ≤ k ≤ 6, -38 ≤ l ≤ 38
47305
2825 [R(int) = 0.0476]
2574
99.7 %
Semi-empirical from equivalents
0.937 and 0.768
SHELXT-2014/5 (Sheldrick, 2014)
SHELXL-2014/7 (Sheldrick, 2014)
2825 / 0 / 200
1.052
R1 = 0.0282, wR2 = 0.0690
R1 = 0.0318, wR2 = 0.0707
0.192 and -0.197 e.Å-3
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Figure 1-35. Thermal ellipsoid plot and the full numbering scheme of 1-29 (007-15060).
All atoms shown are depicted with 50% thermal contours. The hydrogen atoms are
shown as spheres. The chirality of atom C2 is S; C12 is S.
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Table 1-9. Crystal data and structure refinement for 1-29 (007-15060).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal size
Crystal color and habit
Diffractometer
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Observed reflections (I > 2σ(I))
Completeness to θ = 66.580°
Absorption correction
Max. and min. transmission
Solution method
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I)]
R indices (all data)
Largest diff. peak and hole

007-15060
C18H22O4
302.35
93(2) K
1.54178 Å
Monoclinic
P 21/c
a = 12.8744(9) Å
α = 90°.
b = 13.5401(9) Å
β = 104.358(4)°.
c = 9.4132(7) Å
γ = 90°.
3
1589.7(2) Å
4
1.263 Mg/m3
0.717 mm-1
648
0.200 x 0.200 x 0.090 mm3
Colorless Prism
Rigaku Saturn 944+ CCD
3.544 to 66.580°.
-15 ≤ h ≤ 15, -15 ≤ k ≤ 15, -11 ≤ l ≤ 11
49323
2784 [R(int) = 0.0879]
2355
98.9 %
Semi-empirical from equivalents
0.938 and 0.684
SHELXT-2014/5 (Sheldrick, 2014)
SHELXL-2014/7 (Sheldrick, 2014)
2784 / 0 / 200
1.049
R1 = 0.0356, wR2 = 0.0934
R1 = 0.0440, wR2 = 0.1008
0.230 and -0.266 e.Å-3
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Figure 1-36. Thermal ellipsoid plot of 1-30 (007_13099). All atoms shown are depicted
with 50% thermal contours. The hydrogen atoms are shown as spheres.
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Table 1-10. Crystal data and structure refinement for 1-30 (007_13099).
Identification code
Empirical formula
Formula weight
Temperature
Wavelength
Crystal system
Space group
Unit cell dimensions

Volume
Z
Density (calculated)
Absorption coefficient
F(000)
Crystal color
Crystal size
Θ range for data collection
Index ranges
Reflections collected
Independent reflections
Completeness to θ = 65.048°
Absorption correction
Max. and min. transmission
Refinement method
Data / restraints / parameters
Goodness-of-fit on F2
Final R indices [I>2σ(I) = 2490 data]
R indices (all data)
Largest diff. peak and hole

007_13099
C18H22O4
302.35
93(2) K
1.54178 Å
Monoclinic
P 21/c
a = 12.2539(10) Å
b = 5.61320(10) Å
c = 23.7795(4) Å
1590.63(15) Å3

a = 90°
b = 103.473(8)°
g = 90°

4
1.263 Mg/m3
0.716 mm-1
648
Colorless
0.220 x 0.110 x 0.090 mm3
3.709 to 65.048°
-14 ≤ h ≤ 14, -6 ≤ k ≤ 6, -24 ≤ l ≤ 27
24316
2673 [R(int) = 0.0447]
98.2 %
Semi-empirical from equivalents
0.938 and 0.818
Full-matrix least-squares on F2
2673 / 0 / 200
1.027
R1 = 0.0316, wR2 = 0.0848
R1 = 0.0344, wR2 = 0.0890
0.200 and -0.173 e.Å-3
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Computational details for energy minization experiments

Quantum chemical calculations were performed using Gaussian 09. Geometry
optimization and vibrational frequency calculations in the gas phase were carried out at
the M06-2x/6-31+g(d) level of theory. The M06-2x functional was selected over other
popular density functionals due to its adequate description of noncovalent interactions in
macrocycles. Stationary points were characterized by frequency calculations at 298 K,
with structures at energy minima showing no negative frequencies and transition-states
showing one negative frequency. All energy values are zero point corrected and shown
are in kcal mol-1, bond lengths are reported in Ångstroms (Å), and bond angles in degrees
(˚). Molecular figures were generated using CYLView.

Computational experiments designed to determine the effect of the configuration at the
stereogenic center to the preference for a specific planar chirality of monosubstituted
[13]-mcrodilacone.
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Chapter 2
A cardiac glycoside activities link Na+/K+ ATPase ion-transport to breast cancer
migration via correlative SAR
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2.1 Introduction to cell migration
In its simplest definition, cell migration refers to the translation of the whole cell
body from one location to another1. It is a highly complex and dynamic process that is
tightly regulated and coordinated spatially and temporally. In general, migration begins
when a cell responds to an external signal to migrate through polarization or formation of
distinct front and rear part. The front part forms a protrusion in the direction of migration,
which is then attached to the substratum by adhesion molecules. At the leading edge of
this protrusion, actin polymerization generates contraction forces, which move the cell
forward. At the rear, actin depolymerization retracts the cell and adhesion molecules
detach the rear portion from the substratum. The specific details (mechanics, mechanisms
and regulation) of each of these processes comprise a huge current research field.
Cell migration is a fundamental cellular process that is critical for a number of
physiological and pathological phenomena such as wound healing2, tissue remodeling,
angiogenesis, and cancer metastasis3. Because of the highly complex nature of the
choreography, mechanics and regulation of cell migration, no complete model that
incorporates all of its components currently exists. One of the major problems in
determining the precise roles of each of the proteins involved in cell migration is the lack
of potent and selective inhibitors for the functions of these proteins. Besides their
therapeutic potential, small-molecule inhibitors of cell migration serve as valuable tools
to probe the molecular basis of cell motility4.
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2.2. Small molecule inhibitors of cell migration
Most of the reported small molecule inhibitors of cell migration (Fig. 2-1) target
the two major parts of cell migration machinery, the microtubule and actin. Some of the
small molecules that inhibit cell migration by affecting the microtubule include
colchicine, which inhibits tubulin polymerization and destabilizes the microtubule5 and
taxol, which, in contrast to colchicine, is a microtubule-stabilizing agent6. Those that
modulate actin functions can be superficially classified as (1) actin-filament destabilizers
(2) actin filament-stabilizers and (3) inhibitors of actin-binding and actin-regulatory
proteins4. Examples of actin-filament destabilizers include cytochalasin B, cytochalasin
D and latrunculin A. Cytochalsin is the most highly characterized microtubule
destabilizer which acts by binding and blocking the end of actin filaments and thus
inhibiting dynamics at this end of the filament7. Among actin filament-stabilizer, the most
popular is phalloidin, a phallotoxin from a poisonous mushroom. Phalloidin, although not
cell penetrable, is a very useful probe molecule commonly conjugated to a fluorophore
and used for visualizing F-actin7. Jasplakinolide, on the other hand, is a cell-permeable
actin-stabilizer8.
In contrast to the vast number of small molecules that affect cell migration by
modulating the activities of actin and microtubules, there are only very few that targets
actin-binding proteins and actin-regulatory proteins and thus new small molecules that
target these proteins will be valuable for understanding the regulatory mechanism of actin
dynamics. Some examples include blebistatin (an inhibitor of class II-skeletal muscle
myosin)9, synthetic naphthalenesulfonamide, ML-9 (inhibitor of myosin light chain
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kinase)10 and synthetic pyridine derivative Y-27632, an inhibitor of Rho-associated
kinase11.
There are also a few cell migration inhibitors whose target is unknown. One
example is the 15-membered macrocyclic natural product Motuporamine C extracted
from a marine sponge Xestospongia exigua12. It was found to inhibit tumor cell invasion
and angiogenesis13. Finding the biomolecular target of cell migration inhibitors could
contribute to the complete understanding of cell migration. The small molecules
previously discussed exemplify mechanisms of actions that have already been identified.
With the advances in screening technologies as well as small molecule library generation,
more useful probes are expected to be discovered and will continue to push the boundary
of knowledge in the field of cell migration. Please refer to an excellent review article4 for
a more thorough discussion of cell migration inhibitors.
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Fig. 2-1. Representative small molecule inhibitors of cell migration.
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2.3 Chemical genetics screening for cell sheet migration using a HTS scratch-wound
assay
Collective cell migration, although less studied than individual cell migration, is
the mode of migration that is operative in physiological processes such as wound healing,
gastrulation, tissue repair and cancer metastasis14. Single cells must abandon their
individual migratory behavior and coordinate their cytoskeletal activities with adjacent
cells across cell-cell junctions in order to migrate collectively as a cell sheet. Assays that
can recapitulate this mode of migration constitute valuable methods for understanding the
fundamental mechanisms and mechanics of collective cell migration.
Cultured epithelial cells provide a great model system for understanding
collective cell migration as well as interactions of cells in a sheet. Scratching the
monolayer of epithelial cells creates a gap or ‘wound’ that can initiate the migration of
cells towards the wound; this is the process of wound closure (Fig. 2-2). Movement of the
cell sheet during wound closure in cultured epithelial cells is very similar to cell sheet
movement in vivo during the re-epithelialization step of wound healing and during
embryonic morphogenesis of various organisms15. Madin-Darby canine kidney (MDCK)
cells are one of the widely used cell line for investigating collective cell migration using
the wound-closure or scratch-wound assay. MDCK cells move as a cohesive and
coherent sheet of cells without loss of cell-cell contact with multiple rows of cells
actively contributing to cell sheet movement through protrusive cell crawling16.
The Fenteany lab adapted the MDCK cell scratch-wound assay to a highthroughput format and used this for chemical genetic screening of epithelial cell sheet
migration inhibitors17. The ‘quantitative’ version of scratch-wound assay begins with
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addition of either a test compound or a DMSO control in a confluent monolayer of
MDCK cells. Mechanical wounding of the monolayer (using a pipette tip) introduces a
circular wound, which triggers the collective cell migration of the epithelial sheet (Fig. 22). The rate of collective cell sheet migration is measured by quantifying the progress of
wound-closure, which in turn is monitored by taking pictures of each well at different
time points. The remaining open area at each time-point is calculated by tracing the
wound margin in each image using the ImageJ software. For high-throughput screening,
an ‘end-point’ version of the scratch-wound assay is done. In this version, the test
compounds are only assayed at one concentration and the compound is considered active
if the wound area is still open at a time point when the DMSO-treated well is already
closed. To verify and carefully characterize the antimigratory activity of the active
compounds, the previously described quantitative wound-closure assay is used where
multiple concentrations of active compounds are assayed to generate a dose-response
curve, % inhibition and IC50 values.

Fig. 2-2. Scratch-wound assay of DX-52-1. The figure was re-used with permission.
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Using this strategy, the Fenteany lab discovered new small molecule inhibitors of
epithelial cell sheet migration with new protein targets and mechanisms of actions. Some
of the small molecules discovered using this strategy include the small molecule DX-52
and locostatin (Fig. 2-3). DX-52 is an analog of the natural product quinocarmycin that
targets radixin and inhibited the epithelial cell sheet migration by disrupting the
interaction of radixin and actin16. This small molecule helped clarify the role of radixin in
epithelial cell sheet migration where G protein-coupled receptor kinase 2 (GRK2) was
found to activate radixin leading to the regulation of membrane protrusion in migrating
epithelial cells18. Locostatin on the other hand, targets RKIP and inhibited the cell
migration by disrupting the RKIP-Raf 1 interaction19. Locostatin has been a valuable
probe molecule in understanding the role of RKIP in epithelial and cancer cell migration,
invasion and metastasis20.
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Fig. 2-3. Representative epithelial cell sheet migration small molecule probe
discovered through high throughput scratch-wound assay in MDCK cells.
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2.4 Chemical genetics screening for breast cancer cell migration
The same high-throughput scratch-wound assay was adapted to a 96-well plate
format to screen compound libraries for inhibitors of triple-negative breast cancer cell
migration. Triple negative cells are a type of breast cancer that is refractory to current
chemotherapeutic options. Instead of MDCK cells, immortalized triple negative breast
cancer cell lines (BT20 and MDA-MB-231) were used to screen three compound libraries.
The first library screened was a small collection of [13]-macrodilactones and
carbohydrate-fused [13]-macrodilcatones synthesized in the Peczuh Lab. The next
compound libraries screened were commercial chemical libraries of natural product (880
compounds) and synthetic small molecules (12,720 compounds) from the companies
Analyticon and Chembridge respectively. The screening strategy starts at 50 µM
concentration. Active compounds at this concentration are then cherry-picked and
rescreened at lower concentrations (Table 2-1). New small molecule probes for cell
migration were discovered from this screening effort, which could potentially be
followed up for further SAR, target ID and mechanism of action studies. The next
paragraphs will briefly describe the results of these screening efforts. The full list and
structure of small molecule ‘hits’ from the Analyticon natural product library can be
found in the Appendix.
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Table 2-1. Screening of three compound libraries for MDA-MB-231 breast cancer cell
migration inhibitors
Concentration
50 µM
10 µM
2 µM
400 nM
80 nM

PZ library (9
compounds)
(3)

Natural product
(880 compounds)
(55)
6%
(13)
1.5 %
(10)
1.1 %
(6)
0.7 %
(6)
0.7 %

Synthetic small molecules
(12,720 compounds)
1,232
10 %
43
0.4 %
28
0.2 %
19
0.1 %
0
0%

2.4.1 Results and discussion for screening of [13]-macrodilactone library
The triple negative breast cancer cell line BT20 was used to screen the small
macrocyle library from the Peczuh Lab. In this effort, an octylglucoside-fused [13]macrodilactones 2-1, 2-2 and 2-3 (Fig. 2-4) were found to inhibit the migration of this
cell line at 30-50 µM concentrations. An SAR study was done to further characterize
their antimigratory activity. The full details of this project can be found in the published
report21. This section of this thesis chapter will only summarize the important results and
include one new interpretation for the SAR data in light of the new insights learned from
the first chapter.
The active compounds 2-1, 2-2 and 2-3 (Table 2-2) discovered from the initial
qualitative scratch-wound assay were eventually found to have a low therapeutic index.
Therapeutic index is the ratio of MLC (maximum lethal concentration) to MIC (minimum
inhibitory concentration) when assayed using the quantitative scratch-wound assay and
thus prevented the determination of IC50 values. We hypothesized that the low
therapeutic index is due to the cytostatic or cytotoxic activities of these compounds. To
test this hypothesis, the compounds were evaluated in a cell viability assay using the cellcounting kit 8 (CCK8) – a highly water soluble tetrazolium salt. The intermediate
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molecules (synthetic precursors) 2-5, 2-6 and 2-7 during the synthesis of the
octylglucoside-fused [13]-macrodilactones were also evaluated for their antiproliferative
and cytotoxic activities (Table 2-2).
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Fig. 2-4. Representative carbohydrate-fused [13]-macrodilactones and synthetic
precursors tested for cell viability assay. The top compounds are octylglucoside-fused
[13]-macrodilactones while the bottoms ones are some of the intermediate molecules
during the synthesis. Compounds 2-1, 2-2 and 2-3 were the octylglucoside-fused [13]macrodilactones active at the qualitative scratch-wound assays.

Table 2-2. SAR in cell viability assay
Compound

MIC
(µM)

IC50
(µM)

95% CI
(µM)

MLC
(µM)

2-1
2-2
2-3
2-4
2-5
2-6
2-7

10
50
50
10
25
25
10

85.1
91.4
107
38.1
52.9
61.1
47.1

82.8 – 87.4
89.2 – 93.6
102.6 – 111.5
37.3 – 38.8
51.2 – 53.8
60.1 – 60.2
43.8 – 50.1

300
300
> 300
50
75
100
75

Therapeutic
Index
(MLC/MIC)
30
6
6
5
3
4
7.5
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In the cell viability assay, all the active compounds contain an octylglucoside
moiety, which suggest that the pharmacophore for the antiproliferative activities of this
family of compounds is octylglucoside itself (Table 2-2). The IC50 of all the active
compounds fall within the same range. However, the toxicity and the therapeutic index
considerably vary with the identity of the fused cyclic molecule with compound 2-1 (with
a fused [13]-macrodilactone and with a benzyl protection at C2, C3 hydroxyl of the sugar
moiety) having at most 10-fold higher therapeutic index. In chapter one, we observed that
the [13]-macrodilactone adopts different shapes depending on the configuration of the
stereogenic plane and the stereogenic centers on the ring. It is possible that the
improvement in therapeutic profile of 2-1 resulted from an optimized ring scaffold that
allowed for better orientation of the pharmacophoric unit – the octyl glucoside – around
the binding site of its target biomolecule. This suggests that varying or fine-tuning the
macrocycle attached or fused to a pharmacophore of bioactive small molecules can
potentially optimize the biological properties of these molecules.

2.4.2 Results and discussion for screening of Chembridge synthetic compound library
From the 12, 720 Chembridge synthetic small molecule library, only 1,232 were
active at 50µM, which is 10% of the total number of molecules screened (Table 2-1). The
hit rate at lower concentrations is 0.4%, 0.2%, 0.1% at 10µM, 2µM and 400nM
respectively with no compounds active at concentrations lower than 400nM. This hit rate
is lower than the hit rate for the natural product compound library, which is expected for
synthetic compound libraries. However, the structures of the molecule hits from synthetic
compound library are significantly less complicated than the natural product and thus
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would be more amenable for SAR studies. Moreover, the synthetic molecule hits are
more likely to be novel structures (less explored than natural product molecules) with
potentially novel target and mechanisms of action and thus have huge potential as small
molecule probes. The most promising hits, among the 19 synthetic small molecules active
at 400nM, are shown in Fig. 2-5. These six molecules are not toxic at this concentration
and the wound-area of MDA-MB-231 monolayer treated with these compounds is still
widely open after 24 hours compared to the DMSO-treated cells. These molecules can be
good lead compounds for SAR, target ID and mechanisms of action studies.
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Figure 2-5. Most promising hits from screening of Chembridge synthetic compound
library for MDA-MB-231 breast cancer cell migration inhibitors.
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2.4.3 Results and discussion for screening of Analyticon natural product compound
library
The hit rate for natural product library screening is higher (6%, 1.4%, 1.0%, 0.7%,
0.7% at 50µM, 10µM, 2µM, 400nM, 80nM respectively) than the hit rate for synthetic
small molecule screening (Table 2-1). This is to be expected since the natural product is
most likely to be biologically active. The structures of the natural product hits at 50 µM
are shown in Appendix with the corresponding toxicity profiles as assessed using a
qualitative trypan blue assay22. Some of the natural product families found were:
cinchona alkaloids (5 compounds) – antimalarial; tricothecenes (5) – protein synthesis
inhibitors; thapsigargins (4) – Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA)
inhibitors; Sesquiterpenes (5); Indoloquinolizidines (4); Cardiac glycosides (9);
colchicine (1) – microtubule polymerization inhibitor; curvularin (1) and other alkaloids.
The most promising compounds were further characterized using the quantitative scratchwound assay. The antimigartory activity profile of some of these compounds is
summarized in Table 2-4 and the full data for all the compounds characterized can be
found in Appendix. Among these natural product hits, ouabain was chosen as a lead
compound for further characterization.
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Table 2-3. Antimigratory profiles of the most promising hits from the analyticon natural
product compound screening.
Compound

MIC
(µM)

IC50
(µM)

MLC
(µM)

TI
(µM)

6.25

NA

12.5

2

6.25

5.8

25

4

3.125

36

> 50

> 16

0.061

0.173

>100

>1600

curvularin

cardiac glycoside (ouabain)
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2.5 Cardiac glycosides as potent and selective inhibitor of Na+/K+ ATPase
In the course of screening libraries of small molecule and natural product
compounds for cell migration inhibitors using our scratch-wound assay, cardiac
glycosides were found to inhibit the migration of the human triple-negative breast cancer
cell line MDA-MB-231 at submicromolar concentrations. The MDA-MB-231 line is a
cellular model for triple-negative breast cancer, which is refractory to current
chemotherapeutic options23. This chapter investigates how cardiac glycoside inhibited the
migration of MDA-MB-231 breast cancer cells.

2.5.1 Cardiac glycosides – structural features and biological activities
Cardiac glycosides also referred to as cardiotonic steroids, are a group of natural
products that share a common ‘unique’ steroidal core that is doubly substituted with a
sugar at position 3 and an unsaturated lactone ring at position 17 (Fig. 2-6).
Classification of cardiac glycosides depends on the type of lactone ring attached to the
steroidal core where those with the lactone 2-furanone are called cardenolides (e.g.,
ouabain – the most highly studied cardiac glycoside, digitoxin and UNBS1450) and those
with lactone 2-pyrone are called bufadienolides (e.g., bufalin and marinobufagenin). The
C3 position can be ornate with different types and numbers of sugars such as glucose,
rhamnose etc. The steroidal core is also ornate with various substituents at different
positions but the unique cic/cis configuration at the A/B and C/D ring junctions is
preserved through out the entire cardiac glycoside family. This unique configuration at
the two ring junctions resulted to a cup-shaped structure - with two distinct α and β
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surfaces (Fig. 2-6 – top right structure) - rather than the flat planar structure inherent to
common steroids with trans configurations.
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Fig. 2-6. Structural properties of cardiac glycosides and representative members of
cardiac glycoside family.
A number of cardiac glycosides such as digitoxin have long been used as positive
inotropic drugs for treatment of congestive heart failure by inhibiting the Na+ and K+
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antiport activity of Na+/K+ ATPase24. Over the last 20 years, interest in cardiac glycosides
has grown tremendously due to their promising anti-cancer properties25 . The steroid core
with distinct cis confiugrations at the A/B and C/D ring junctures is the active
pharmacophore26 . It is the minimum structure required for Na+ pump inhibition through
induction of protein conformational change at the receptor level. The lactone ring is not
rigorously part of the pharmacophore but it amplifies the affinity of the steroid core with
the protein. The sugar moiety affects the potency as well as the pharmacokinetic and
pharmacodynamic properties of the cardiac glycosides27. This SAR information is only a
fraction of the numerous studies on the SAR of various cardiac glycosides with respect to
inhibition of Na+/K+ ATPase and its anti-cancer activities. However, no SAR study that is
focused on the antimigratory activity of cardiac glycosides in breast cancer cells has been
reported.

2.5.2 Na+/K+ ATPase – a multifunctional protein
Na+/K+ ATPase, the largest member of P-type cation pumps, is responsible for the
transport of three Na+ ions out of and two K+ ions into the cell against their physiological
concentration gradient28. This transport is powered by ATP hydrolysis and is estimated to
account for 30% of all cell’s energy consumption at rest29. Active transport of Na+ and K+
ions in and out of the cell generates an electric potential gradient across the plasma
membrane and maintains the resting potential of cells and thus the activity of this pump is
critical for regulation of cell volume, contraction of heart muscle cells and mobilization
of ions such as calcium and other molecules in and out of the cell28.
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Fig. 2-7. Cartoon representation of X-ray cystal structure of the high-affinity Na+/K+
ATPase E2P–ouabain complex (3.4 A resolution)30. The E2P–ouabain complex is
depicted using the following color codes: red [nucleotide binding (N) domain], blue
[phosphorylation (P) domain], light yellow [actuator (A) domain], orange (αM1–2), teal
(αM3–4), purple (αM5–6), brown (αM7–10), green (β-subunit), and deep pink (γsubunit). The CTS binding site is marked CTS. Ouabain is represented by yellow sticks,
Mg2+ and the three water molecules by light green and red spheres, respectively. The
figure was reused from reference 30.
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In general the Na+/K+ ATPase consists of three subunits (Fig. 2-7)30. The larger α
subunit is the catalytic site. It contains the nucleotide binding (N), phosphorylation (P),
and actuator (A) domains, and the biniding sites for Na+, K+, Mg2+ as well as the highly
conserved cardiac glycoside binding site in a vestibule formed by the αM1-M6 helices. It
also contains the controversial phosphorylation sites proposed to be involved in the
signaling function of the Na+/K+ pump31. The β subunit is the extracellular glycoprotein
(green) mainly important for the recruitment of the α subunit to the plasma membrane.
The γ (FXYD) subunit regulates the kinetic properties of the pump as well as its tissue
specificity. To add to the complexity of this pump, the α and β subunits exists in different
isoforms depending on the cell type: the α subunit exists in four isoforms (α1-4) while the
β in three (β1-3)28.
Besides the ion-transport function, the Na+/K+ ATPase also probably has a
signaling function. One theory is that a population of non-pumping Na+/K+ ATPase exist
in a caveolae and forms a multi-protein signaling complex comprised of Src kinase,
epidermal growth-factor receptor (EGFR), inositol 1,4,5 – triphosphate (IP3) receptor,
and caveolins31. This signaling complex was proposed to activate two downstream
signaling pathways. The first one is through the IP3 receptor-mediated calcium release
that affects intracellular calcium oscillation31c. The second one is a protein-kinase
cascade initiated by Src31a, 31b. These signaling cascades affect various cellular processes
such as cell growth, motility, gene expression and some metabolic pathways.
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2.5.3 Context-dependent dual mechanisms of actions of cardiac glycosides
Upon binding of cardiac glycosides to the α subunit of Na+/K+ ATPase, various
biological and physiological effects were observed depending on the concentration of
cardiac glycosides and the cell type used. Two mechanisms explain the sometimes,
opposing cellular and physiological effect of cardiac glycoside32.

2.5.3.1 The classical “Na+ lag” model
The Na+ lag model explains the positive inotropic effect of cardiac glycoside and
its use as drugs for treatment of cardiac arrhythmia33. At concentrations >100 nM, cardiac
+

+

glycosides cause the classical inhibition of ion transport function of the Na /K ATPase.
+

This inhibition leads to an increase in intracellular Na ion which then activates the
+

2+

reverse mode of Na /Ca

exchanger resulting in an increased intracellular Ca

2+

concentration. Increase in intracellular calcium leads to increase in muscle contraction,
blood pressure and Na+ excretion (Fig. 2-8a).

2.5.3.2 The Na+K+ ATPase signalosome model
+

+

+

+

The receptor function of Na /K ATPase is explained by the Na /K ATPase
signalosome model31. This model calls for the existence of a population of nonpumping
+

+

Na /K ATPases that resides in a caveoli and act as a scaffold for the assembly of multiprotein signaling domain that transmits signals to different intracellular compartments.
Some members of this complex that has been identified include Src kinase, epidermal
growth-factor receptor (EGFR), inositol 1,4,5-triphosphate (IP3) receptor and caveolins.
The model explains that low concentrations of ouabian is not enough for the inhibition of
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+

+

the pumping Na /K ATPase but is enough to activate the non pumping population and
trigger a signaling cascade that affects a number of cellular processes such as gene
expression, proliferation and adhesion.
At least two signaling mechanisms were proposed to get activated by binding of
+

+

cardiac glycosides to the Na /K ATPase signalosome. The first is the signaling through
alterations in intracellular calcium oscillations31c. Although not yet fully defined, it was
+

+

proposed that phospholipase C (PLC) and IP3 are recruited in the Na /K ATPase
signalosome and forms a functional microdomain. This brings the cytosolic part of the
sodium pump in direct contact with IP3 receptor of the endoplasmic reticulum, which
results to repeated transient oscillation of calcium ions. The other signaling proposed is
through Ras activation31a,
+

31b

(Fig. 2-8b). Binding of low concentrations of cardiac

+

glycoside to the Na /K ATPase signalosome releases Src, which transactivates the
EGFR that eventually lead to activation of mitogen-activated protein (MAP) kinase
cascade that affects various cellular processes under the control of MAP kinase such as
gene expression, proliferation and some metabolic processes.
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Fig. 2-8. Two models that explain the dual mechanisms of actions of cardiac glycosides
are the (a) Na+ lag hypothesis and (b) Na+/K+ ATPase signalosome model. The figure
was reused from reference 32.

2.6 Investigation of the antimigratory mechanism of action of cardiac glycosides in
MDA-MB-231 breast cancer cell migration

2.6.1 Motivation and research question
The dual function of the Na+/K+ ATPase result in dual mechanisms of actions
attributed to cardiac glycoside’s biological activities. The specific operative mechanism
of action of cardiac glycosides is highly dependent on the concentration of cardiac
glycoside and the cell type used. Some examples of the context-dependent mechanism of
action of cardiac glycoside are discussed below.
Some cardiac glycosides inhibit the migration and proliferation of various cell
+

+

types without affecting the ion-transport function of the Na /K ATPase, thus supporting
+

+

the nonclassical Na /K ATPase signalosome model for mode of action of cardiac
glycosides. Marinobufagenin, an endogenous mammalian cardiotonic steroid inhibits
proliferation and growth factor induced migration and invasion of cytotrophoblast and
Chinese hamster ovarian cells in vitro at low nanomolar concentration34 . The mechanism
involved a decrease in ERK1/2 activity and activation of p38 and Jnk pathways. Since
ouabain showed similar activities in both cell lines, they speculated that Na+/K+ ATPase
might be involved; however, no direct correlation was made between inhibition of cell
migration and inhibition of Na+/K+ ATPase35. UNBS-1450 is another novel cardenolide
that inhibited the proliferation and migration of non-small cell lung cancer cells, glioma
cells, prostate cancer cells and metastatic melanoma cells at concentrations that does not
affect the ion transport activity of the pump36. Inhibition of the α sub-unit of Na+/K+
ATPase by UNBS-1450 led to a sharp decrease in intracellular ATP concentration
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causing disorganization of actin cytoskeleton and induction of proautophagic cytotoxic
effects37.
After discovering that cardiac glycosides inhibit the migration of MDA-MB-231
+

+

cells, we endeavored to define the specific role of Na /K ATPase (classical versus
nonclassical) in migration of MDA-MB-231 breast cancer cells. Understanding which of
the two functions of Na+/K+ ATPase is operative in the observed antimigratory activities
of cardiac glycoside in MDA-MB-231 breast cancer cell migration can contribute to a
fundamental understanding of triple negative breast cancer migration and can potentially
open up new avenues for therapeutic interventions.

2.6.2 Research design and strategy
+

To investigate which function of the Na /K

+

ATPase is operative in the

antimigratory activity of cardiac glycosides (CGs); we developed a strategy called
correlative SAR. Traditional SAR studies guide improvements of small molecule potency
and selectivity for a given target. On the other hand, we define correlative SAR as a
strategy to expand the use of existing biologically active compounds to address some of
the major challenges in the postgenomic era: annotating protein functions and linking
those functions to an observed phenotype. In contrast to traditional SAR, correaltive SAR
takes advantage of a distinct pattern of structural requirements for activity by a group of
related molecules (SAR profile) across a series of assays. The SAR profiles are then used
to establish relationships between a protein or cellular system and bona fide biological
processes, that is, linking specific protein function to a cellular phenotype (Fig. 2-9).
Direct correlation of SAR profiles for protein function and a cellular phenotype then
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implicates a role for the protein in the phenotype. The correlative SAR strategy is
especially useful for multifunctional proteins and moonlighting proteins38. Correlative
SAR employs small molecule probes and thus shares the complementarity and
advantages of small molecules over genetics and RNA interference techniques for
annotating protein functions.
+

+

In this study, we use correlative SAR to determine what role the Na /K ATPase
plays (classical versus non-classical) in migration of MDA-MB-231 breast cancer cells
(Fig. 2-9). Our strategy first involved synthesis of analogs containing modifications on
key parts of ouabain and digitoxin – two widely studied cardiac glycosides. The analogs
contain a modification on the sugar, steroid core or lactone ring of each CG. Next, SAR
was established at different levels of resolution with respect to inhibition of cell
+

+

migration (cellular), inhibition of the Na /K ATPase activity in vitro (molecular), and
+

+

orientation in the cardiac glycoside binding site of Na /K ATPase (atomic). We
evaluated whether inhibition of cell migration was separable from inhibition of the
+

+

Na /K antiport pump by correlating the SAR profiles of ouabain in each of these assays.
In addition, to determine whether the inhibition of cell migration resulted from general
+

+

inhibition of the Na /K ATPase or if it is confined to an effect of CGs, other structurally
+

+

unique Na /K ATPase inhibitors were tested for their antimigratory activity. A small
molecule inhibitor that does not activate the Src signaling pathway but inhibits the ion
pump was also tested in the cell migration assay. To our knowledge, no SAR study on the
antimigratory activity of cardiac glycosides in MDA-MB-231 breast cancer cells has
been reported prior to this work. Furthermore, the current study shows the utility of
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correlative SAR to establish links between specific protein functions and cellular
phenotypes.
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Fig. 2-9. Research strategy – correlative SAR. The pattern of activity modulation by different analogs in different
assays (i.e. correspondence in decrease in potency between different analogs) is used as a probe to link various
biochemical and cellular activities of small molecules. If the pattern correlates, then the biological activities are
more probably directly related. Three analogs of a cardiac glycoside, ouabain, was synthesized and assayed with
+
+
respect to inhibition of cell migration (cellular), inhibition of the Na /K ATPase activity in vitro (molecular), and
+
+
orientation in the cardiac glycoside binding site of Na /K ATPase (atomic). The SAR profiles in each of these
+
+
assays were correlated to look at the relationship between ouabain- Na /K ATPase interaction at atomic and
molecular level and the observed effect of ouabain in cellular migration.

2.7 Correlative SAR of ouabain and analogs in cellular and molecular level
2.7.1 Semi-synthesis of ouabain analogs
Three analogs of ouabain 2-8 were synthesized (2-9 – 2-11, Scheme 1) by
methods that had been reported previously in the literature39. The derivatives were
prepared, starting from ouabain itself, by removal of the sugar moiety (2-9), reduction of
the lactone ring (2-10) and modification of the steroid core (2-11). Hydrolysis of the
glycosidic linkage between the L-rhamnose and steroid core provided ouabagenin 2-9.
Reduction of the butenolide olefin by hydrogenation provided analog 2-10. Compound 211 contains an acetonide group that links the C1 and C19 hydroxyl groups. The analogs
were chosen because they were synthetically accessible and because they consisted of
variations of the key structural segments of the parent compound in a way that would
allow for a reasonably comprehensive SAR profile.
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Scheme 2-1. Semi-synthesis of ouabain analogs.

2.7.2 SAR profile of ouabain and analogs in MDA-MB-231 breast cancer cell
migration assay
The MDA-MB-231 breast cancer cell line was chosen for the scratch-wound cell
migration assay. MDA-MB-231, a cellular model for triple negative breast cancer has an
invasive phenotype and is metastatic in animal models. The assay involved mechanical
wounding of a confluent monolayer of cells with a pipet tip after treatment with different
concentrations of compounds or DMSO (vehicle) alone. The progress of wound closure
was monitored by analysis of digital microscope images of the wounds at different times
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postwounding. The area of the wound at each time point was calculated with the publicdomain ImageJ program, and statistical significance was tested with a two-tailed
Student’s t-test. Three independent experiments were done with triplicates for each
concentration of each compound.

Fig. 2-10. IC50 curves for cell migration inhibition by ouabain 2-8 and analogs 2-9 to 211.

Based on the IC50 values for inhibition of wound closure (Fig. 2-10 and Table 24), none of the synthesized analogs was more potent than the parent compound, ouabain
2-8 with an IC50 of 173 nM. However, the potency of the analogs varied with respect to
the type of modification made to the structure of 2-8. Ouabagenin 2-9, which lacks the
sugar moiety, had an IC50 value of 790 nM. The olefin of the butenolide was reduced to
prepare compound 2-10; its IC50 of 4.3 µM demonstrates that a simple modification to the
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lactone segment results in a drop in potency by a factor of 25. It further suggests that the
olefin is relatively important to the ability of cardiac glycosides to inhibit cell migration.
A major decrease in potency (178-fold) was observed for ouabain analog 2-11, which
contains a C1, C19 acetonide group. Modification to the steroid core and specifically the
introduction of a bulky group on the concave face of the cup-shaped steroid greatly
reduced the antimigratory activity of ouabain. The SAR profile (pattern of structural
requirement for activity modulation) for antimigratory activity is: modification on steroid
core > modification on lactone ring > modification on sugar in decreasing impact on
potency (Fig. 2-11a).

2.7.3 Correlative SAR of ouabain and analogs in MDA-MB-231 breast cancer cell
migration assay (cellular level) and Na/K ATPase assay (molecular level)
+

+

+

Ouabain is a potent and specific inhibitor of the Na /K ATPase. The Na /K

+

+

ATPase is a transmembrane antiport ion transporter that pumps three Na ions out of the
+

cell for every two K ions pumped into the cell against their concentration gradients for
each molecule of ATP hydrolyzed. Besides its ion-transport function, this protein
complex also functions as a receptor for ouabain and has been implicated in processes
and key cellular elements that affect cell motility such as cell tight junctions40 cell
contacts41 and actin dynamics42. We investigated whether the antimigratory effect of
+

+

ouabain was linked to the classical inhibition of Na /K ATPase or stimulation of its
receptor function31 using correlative SAR. Specifically, we looked at the SAR profile of
+

+

ouabain in a Na /K ATPase activity assay and correlated it to the SAR profile for
antimigratory activity.
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Table 2-4. IC50 values (µM) for the inhibitory activity of ouabain and analogs in the
Na+/K+ ATPase assay and cell migration assay
Na+/K+ ATPase

Cell migration

Ouabain and
analogs

IC50 (µM)

95% CI

IC50

95% CI

2-8 (ouabain)

0.105

0.031 - 0.352

0.173

0.100-0.300

2-9

0.669

0.526 – 0.850

0.790

0.637 – 0.979

2-10

2.6

0.823 – 8.46

4.3

3.02 – 6.21

2-11

12.4

8.98 – 17.2

30.9

25.2 – 38.0

+

+

The SAR profile in Na /K ATPase inhibition is similar to inhibition of cell
migration (Table 2-4 and Fig. 2-11a). Compound 2-9, with the cleaved sugar moiety, had
a potency that is relatively similar to the parent compound ouabain 2-8. This implies that
+

+

for inhibition of Na /K ATPase activity, as for inhibition of cell migration, the sugar
moiety is less important than other parts of the molecule. Compound 2-10, with the
saturated lactone ring, displays the next lowest decrease in potency, while 2-11, with the
bulky acetonide group on the steroid core, shows the greatest decrease in potency. The
+

+

IC50 values of ouabain and its analogs for inhibition of Na /K ATPase activity and the
values for inhibition of cell migration fall within the same range. The distinct pattern of
+

+

modulation in Na /K ATPase activity by ouabain and the analogs, as measured by both
IC50 (Figs. 2-11a,b) and dose–response for ouabain alone (Fig. 2-11c) and for combined
ouabain and analogs (Fig. 2-11d) correlates well with the pattern observed for their effect
on cell migration. The correlation suggests that the inhibition of cell migration is directly
+

+

related to the inhibition of Na /K ATPase activity.
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of ouabain and analogs in the antimigratory assay and the Na /K ATPase assay (correlative SAR). (C) Pearson correlation
+
+
plot for ouabain’s inhibition of Na /K ATPase and cell migration at different concentrations. (D) Pearson correlation plot
+
+
for inhibition of Na /K ATPase and cell migration by ouabain and analogs at different concentrations.

Fig. 2-11. Correlative SAR of ouabain and analogs at molecular and cellular levels. (A) Decrease in potency of ouabain
+
+
analogs in the cell migration assay and the Na /K ATPase assay (SAR profile). (B) Pearson correlation plot for IC50 values

C)
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2.8 Correlative SAR of digitoxin and analogs in cellular and molecular levels
We were curious to see if the SAR results for ouabain apply to other members of
cardiac glycoside family of natural products. Evidence showed that ouabain and digitalis
cardiac glycosides develop their effect in different cellular spaces and thus have different
therapeutic profiles43. Ouabain’s mode of action starts by binding to the α subunit of the
Na+/K+ pump from the extracellular side. This binding affects cellular functions either
through activation of different signal transduction pathways (Src and IP3) or through
perturbation of intracellular Na+, K+ and Ca+ ion concentrations. Digitalis cardiac
glycosides such as digitoxin on the other hand penetrates the cell’s interior and interacts
with intracellular ryanodine receptors leading to the release of Ca2+ from the
sarcoplasmic reticulum43. To explore if the SAR-correlation results for ouabain applies to
other cardiac glycosides, analogs of digitoxin were synthesized employing the same
transformation as that used for ouabain 2-8 followed by correlative SAR. It would be
interesting to know if the correlative SAR for digitoxin would be similar to ouabain
despite having different modes of action.
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2.8.1 Semisynthesis of digitoxin and analogs
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Scheme 2-2. Semi-synthesis of digitoxin analogs 2-13 to 2-15.

Scheme 2 shows the reactions for the partial synthesis of digitoxin analogs 2-13 to
2-15. An additional product from the deglycosylation of digitoxin, a side product (2-15a,
2-15b), was obtained which was found to be a mixture of alkene isomers produced from
dehydration across the hydroxyl-containing carbon of rings C and D and the carbon
directly adjacent to it which is at the junction of rings B and C. Similar to ouabain
analogs, the synthesized digitoxin analogs each contains modification on either the sugar,
lactone or steroid core. Compound 2-13 contains modification on sugar, compound 2-14
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on lactone ring while compounds 2-15a and 2-15b contain modification on the cup
shaped steroidal core.

2.8.2 Correlative SAR of digitoxin and analogs in MDA-MB-231 breast cancer cell
migration assay (cellular level) and Na+/K+ ATPase assay (molecular level)
The same experimental approach (correlative SAR) done on oubain and analogs
(2-8 to 2-11) was performed on digitoxin and analogs (2-12 to 2-15). The results (Table
2-5 and Fig. 2-12) were similar to that of the ouabain series. A SAR trend in cell
migration inhibition assay was observed in Na+/K+ ATPase assay (Fig. 2-12a). The
analog in which sugar is cleaved is the most potent (compound 2-13) followed by
compound 2-14 with modification on the lactone ring and the least potent ones are
compounds 2-15a and 2-15b with modification on the steroid core. Similar to addition of
a bulky acetonide group that links the C1 and C19 hydroxyl groups of oubain’s steroidal
core, introduction of unsaturation to either ring B or C of digitoxin through the
dehydration of the C-14 hydroxyl greatly reduced the potency of digitoxin. These results
imply that, similar to oubain, the sugar is not that important while the structure of the
steroid core is highly necessary for the inhibition of both cell migration and Na+/K+
ATPase. However, it seemed like modifying the structure of digitoxin has more
pronounced effect in its ability to inhibit Na+/K+ ATPase than in its ability to inhibit cell
migration as shown by the decrease in potency of digitoxin analogs for the two assays
(Fig. 2-12a). Again, similar to the correlation of oubain SAR, the IC50s of digitoxin for
both antimigratory and Na+/K+ ATPase assays correlate very well (Fig. 2-12b). This
result corroborates the initial conclusion that the observed antimigratory effect of cardiac
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glycosides in MDA-MB-231 breast cancer cells is due to the inhibition of Na+/K+
+

ATPase’s ion-transport function. The direct relationship between inhibition of Na /K

+

ATPase ion transport function and inhibition of cell migration seemed to be applicable to
other members of the cardiac glycoside family of natural products.

Table 2-5. IC50 values (µM) for the inhibitory activity of digitoxin and analogs in Na+/K+
ATPase assay and cell migration assay.

2-12 (digitoxin)

IC50 (µM)
Na /K ATPase inhibition
0.005

IC50 (µM)
cell migration inhibition
0.046

2-13

0.097

0.260

2-14

0.691

2.15

2-15a and 2-15b

3.2

10.8

Digitoxin and analogs

+

+

4
IC50 Na+/K+ ATPase
inhibition

b)

r2 = 0.9997

3
2
1
0

0

5

10

15

IC50 cell migration inhibition

Fig. 2-12. (a) Decrease in potency of digitoxin analogs in antimigratory assay and
Na+/K+ ATPase assays. (b) Pearson correlation plot for IC50 values of digitoxin and
analogs in antimigratory assay and Na+/K+ ATPase assays.
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2.9 Correlative SAR of ouabain and analogs at cellular, molecular and atomic level
One of the advantages of correlative SAR is its applicability in looking at small
molecule effects in various level of resolution (cellular, molecular and atomic).
Depending on the assay used, which probes for specific biological activities (biochemical
or cellular; in vitro or in cellulo) or specific small molecule-protein interactions (using
either actual small molecule-protein complex crystal structure or molecular docking
experiments), the same set of structurally similar molecules can be used to link specific
biochemical or cellular activities to protein-small molecule interactions at atomic level.
We used molecular docking experiments to probe for SAR of ouabain and its analogs to
its binding site on the Na+/K+ ATPase and use correlative SAR to link it to the SAR
profile in cellular and molecular level discussed previously.

2.9.1 Molecular docking of ouabain and analogs in the α subunit of Na+/K+ ATPase
+

The ouabain binding site on the extracellular side of the α-subunit of the Na /K

+

ATPase is located in a cleft between the transmembrane segments αM1 and αM630, 44
(Fig. 2-13). Two orientations of ouabain to this site were originally proposed, one with
the lactone ring facing toward the cytoplasmic side, as revealed by X-ray crystal structure
studies30, 44a, 44b (Figs. 2-13, 2-14) and the other one with the lactone ring facing toward
the extracellular side, as suggested by a lanthanide-based resonance energy transfer
(LRET) experiment44c. Regardless of the two orientations of ouabain, all structural and
functional studies agreed that the location of the cardiotonic steroid binding site is in the
deep vestibule formed by the tansmembrane helices αM1–M6 (Figs. 2-13, 2-14). Most of
these transmembrane helices constitute the cation permeation path (mapped in Fig. 2-13

144

+

+

and 2-14 as residues in cyan) that traverses the Na /K pump from one side of the
membrane to the other and passes through the ion-binding site II45 (Figs. 2-13, 2-14, red
circle), suggesting that ouabain acts by directly blocking the path of ions to prevent them
from accessing their binding sites (Figs. 2-13, 2-14). Another possibility is that ouabain
binding may lock the cation transport region into a configuration that prevents the pump
from undergoing the conformational change required for ion transport46. Prior to this
work, no experimental evidence linking ouabain’s orientation to the cation permeation
+

+

path and inhibition of Na /K ATPase was available.
+

+

We investigated the interactions of ouabain and its analogs to Na /K ATPase at
the atomic level (Figs. 2-15, 2-16) by molecular docking experiments in an effort to
+

+

rationalize the SAR results with respect to inhibition of Na /K ATPase ion-transport
function and cell migration. Fig. 2-16 shows the overlay between the docked ouabain and
analogs and the actual ouabain-Na+/K+ ATPase crystal structure30. We explored how each
modification on the ouabain structure affects binding energy (evaluated in the form of a
docking score) and orientation relative to ouabain’s structure in the cocrystal (evaluated
in terms of a root-mean-square-deviation, RMSD) (Table 2-6). We then correlated the
SAR profile for calculated RMSD (Fig. 2-17) and binding energy (Fig. 2-18) to the SAR
+

+

profile for inhibition of Na /K ATPase activity and inhibition of cell migration.
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+

+

Fig.2-13. (A) Crystal structure (4HYT) of Na /K ATPase with bound ouabain (orange) showing the binding site for
ouabain – the vestibule formed by the αM1- αM6 helices (yellow). Shown in cyan are the residues involved in the cation
+
permeation path and the K binding site II. Structure in the box is the cup-shaped ouabain structure showing the
hydrophobic α-surface and the polar β-surface.



d)

c)

Fig. 2-14. The binding site of ouabain (orange) includes the residues (cyan) that form the cation permeation path in
Na+/K+ ATPase which traverse the K+ binding site II (red dot), suggesting than ouabian acts by blocking the ion
permeation path. Figure shows the extracellular view of the cation permeation path (a) with bound ouabain (b).
Figures c and d show the same view in space-filling representation.

b)

a)

The observations of the structural interactions of ouabain and its analogs with the
+

+

Na /K ATPase are consistent with the observed experimental SAR profile for their
+

+

inhibition of Na /K ATPase ion-transport function and breast cancer cell migration. The
docked analogs 2-9 and 2-10 (Figs. 2-15b,c), which are the two most potent analogs (5×
and 25× less potent than ouabain, respectively) adapted a similar orientation to the crystal
+

+

structure of ouabain bound to Na /K ATPase (Fig. 2-15a). The concave nonpolar αsurface of ouabain 2-8 (Fig. 2-13 - chemdraw) and analogs 2-9 and 2-10 are stabilized by
hydrophobic residues such as I315, F316, F783, and F786 (Fig. 2-15a-c). The hydroxyl
groups of the polar β-surface, on the other hand, are stabilized by H-bonding interactions
(between C19-OH and the highly conserved C14-OH of cardiac glycosides and N111 and
T797 of αM1 and αM6, respectively). The C14-hydroxyl–T797 interaction for analog 210, however, was slightly shifted, and thus the H-bonding angle was less than ideal (Fig.
2-17), possibly due to reduction of lactone ring olefin. This could explain the 25×
decrease in potency observed for both the pump and cell migration inhibition. On the
other hand, the least potent analog 2-11 (Fig. 2-15d) adapted a different pose in the ion
permeation path altogether (Figs. 2-15d and 2-18). Analog 2-11 took up a shallow
position and was oriented in the opposite direction with its polar β-surface facing the
helices M4 and M5, while the apolar α-surface faced the helices M1, M2, and M6. This
orientation does not allow for H-bonding interactions with Q111 and T797 (Figs. 2-15d
and 2-18), residues identified by mutagenesis studies47 to be critical for ouabain’s
+

+

inhibition of Na /K ATPase. However, the orientation of the docked analog 2-11 is
possibly stabilized by hydrophobic interactions of I315, F316, and F783 with the steroid
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rings C and D, and H-bonding interaction of C19-hydroxyl with E117 instead of Q111
(Figs. 2-15d and 2-18).
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Fig. 2-15. (A) Acual orientation of ouabain in the crystal structure of ouabain-Na+/K+ ATPase complex. Orientations
of docked analog 2-9 (C), docked analog 2-10 (D), and docked analog 2-11 (E) to cardiac glycoside binding site in
+
+
the Na /K ATPase. Shown are the αM1- αM6 helices that form the binding site for oubain. Also shown are the key
residues in the binding site that are responsible for the high-affinity binding of ouabain to the cardiac glycoside
binding site



+

+

Fig. 2-16. Overlay of crystal structure of ouabain-Na /K ATPase complex (ouabain is in orange) with (a) docked
ouabain – green, (b) docked analog 2-9 - cyan, (c) docked analog 2-10 - orange and (d), docked analog 2-11 – purple.
The orientation of docked ouabain to the cardiac glycoside binding site is very similar to the orientation of ouabian in
the actual crystal structure of ouabain-Na+/K+ ATPase complex showing that the molecular docking method used
closely approximate the actual binding orientation of ouabain.



Fig. 2-17. One of the critical interactions for inhibition of Na+/K+ ATPase by cardiac glycoside is the interaction between the
well conserved T797 and C14-OH of oubain (A). This interaction is similarly accessible in (B) analog 2-9 but is not accessible
in (C) analog 2-10, in which the C14-OH was shifted in an orientation that might have resulted to a less ideal H-bonding angle
with T797. This shift in orientation in analog 2-11 could be due to the hydrogenation of the lactone ring olefin of ouabian. The
effect of modifications (deglycosylation (analog 2-9) and hydrogenation (analog 2- 10)) on cardiac glycoside to this critical
hydrogen-bonding interaction might explain the 5x and 25x decrease in potency for analogs 2-9 and 2-10 respectively.



Fig. 2-18. Ouabain (A) and analog 2-11 (B) hydrophobic and H-bonding interactions with amino acid residues in Na+/K+
ATPAse. The orientation of analog 2-11 does not allow for H-bonding interactions with Q111 and T797, residues identified by
mutagenesis studies to be critical for ouabain’s inhibition of Na+/K+ ATPAse. In docked analog 2-11, T797 is now H-bonding
with N111. The high binding energy of analog 2-11 is however possibly stabilized by hydrophobic interactions of I315, F316,
F783 with the steroid rings C and D, and H-bonding interaction of C19-hydroxyl with E117 instead of Q111.

2.9.2 Correlative SAR of ouabain and analogs in MDA-MB-231 breast cancer cell
migration assay, Na+/K+ ATPase assay, binding energy and orientation in Na+/K+
ATPase binding site
The binding energy and RMSD were calculated for the docked compounds to
+

+

quantify the effect of each structural modification on the ouabain-Na /K ATPase
interaction. These parameters were then correlated to the experimental results from in
+

+

vitro Na /K ATPase inhibition and breast cancer cell migration assays (Table 2-6).
Considering that the docking score is only an approximate measure of true free energies
+

+

of binding, both the IC50 values for inhibition of Na /K ATPase and inhibition of cell
migration by ouabain and analogs correlate reasonably well with the calculated binding
energy (Fig. 2-20) for analogs 2-9 and 2-10. That is, analogs 2-9 and 2-10 have less
negative energy of binding compared with 2-8, although with similar orders of magnitude,
which is consistent with lower potency. A proper orientation relative to the cardiac
+

glycoside binding site seemed to be highly critical to Na -pump inhibition (Fig. 2-19).
The more negative binding energy calculated for the least potent analog 2-11 probably
+

+

results from a stable analog 2-11–Na /K ATPase complex (possibly resulting from some
hydrophobic and H-bonding interactions discussed earlier) (Fig. 2-18), but the orientation
of analog 2-11 to the ion permeation path might not be as effective in blocking ion
permeation as that of ouabain. In other words, despite analog 2-11 being more tightly
bound, it is noticeably positioned in a region of the binding site much closer to the
surface, and therefore less able to stop the permeation of ions deep inside the pocket (Figs.
+

2-16d and 2-17d). On the other hand, both the IC50 values for inhibition of Na /K

+
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ATPase and inhibition of cell migration by ouabain analogs correlate very well with the
RMSD (Fig. 2-19), implying that deviation from ouabain’s orientation in the cation
+

+

permeation of Na /K ATPase is directly proportional to the decrease in its inhibitory
activity.

Table 2-6. Calculated binding energies and RMSD of ouabain and analogs from
molecular docking experiments and the IC50 values for cell migration and Na+/K+
ATPase assays
Binding
energy (amber
score) kcal/mol

RMSD (nonhydrogen
atoms)

2-8

–5420.51

0.0000

2-9

–5399.66

0.5807

2-10

–5412.08

0.9367

2-11

–5584.89

6.5933

A)
IC50 Na+/K+ ATPase
inhibition

15

B)

r = 0.9959

10

5
n = 4, p = 0.0041, 95% CI = 0.81-1.00
0
0

2

4

6

8

IC50 cell migration inhibition

Docked
ouabain and
analogs

Na+/K+
ATPase IC50
(µM)
0.105

Cell migration
IC50 (µM)

0.669

0.790

2.6

4.3

12.4

30.9

40

0.173

r = 0.9979

30
20
10
n = 4, p = 0.0021, 95% CI = 0.90-1.00
0
2
-10

4

6

8

RMSD

RMSD

Fig. 2-19. (A) Pearson correlation plot for IC50 values of ouabain and analogs in the
+

+

Na /K ATPase assay and the RMSD. (B) Pearson correlation plot for IC50 values of
ouabain and analogs in the cell migration assay and the RMSD.
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Figure 2-20. (A) Pearson correlation plot for IC50 values of ouabain and analogs in the
+

+

Na /K ATPase assay and the RMSD. (B) Pearson correlation plot for IC50 values of
ouabain and analogs in the cell migration assay and the RMSD.

2.10. Antimigratory activities of other Na+/K+ ATPase inhibitors that are not
structurally related to cardiac glycosides
To explore whether the inhibition of cell migration results from general inhibition
+

+

of the Na /K ATPase or is specific for cardiac glycosides, the antimigratory effect of
+

+

other Na /K ATPase inhibitors that are structurally distinct from cardiac glycosides was
+

+

determined. All of the non-cardiac-glycoside Na /K ATPase inhibitors tested also
inhibited cell migration with varying potencies (Table 2-7). Compound 2-16, a
+

+

nonspecific inhibitor of Na /K ATPase, is the most potent; however, it was also toxic
and its IC50 is very close to its minimum lethal concentration, which is likely due to its
+

effect on other cellular targets. The next most potent is compound 2-18. This Na /K

+

ATPase inhibitor is particularly interesting because it was reported that, unlike ouabain, it
+

+

does not activate the Na /K ATPase/Src complex nor does it stimulate the protein kinase
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cascades48 . Compound 2-18 is a useful small molecule probe since it can inhibit only one
+

+

function (Na /K ATPase enzymatic activity) of the pump without activating its receptor
function. This allows exploration and differentiation of the functional consequences of
+

+

the enzymatic versus receptor function of the Na /K ATPase. Since 2-18 also inhibits
cell migration, the antimigratory activity of cardiac glycosides does not primarily entail
+

activation of the receptor function of Na /K
+

+

ATPase. Furthermore, any of the

+

compounds tested that inhibit Na /K ATPase also inhibit MDA-MB-231 breast cancer
cell migration. Therefore, the cardiac glycosides do not have a unique antimigratory
+

+

effect among inhibitors of the Na /K ATPase.

Table 2-7. Inhibitory effect of Na+/K+ ATPase inhibitors that are structurally different
from cardiac glycoside in the Na+/K+ ATPase assay and the cell migration assay
Literature IC50 for
inhibition of the
Na+/K+ ATPase

Compounds
(2-16)

IC50 for inhibition
of cell migration

Na3VO4
40nM

Minimum lethal
concentration
15.6 µM

49

5.6 µM

50

34.4 µM

>250 µM

7.86 µM

>250 µM

(2-17)
O
. xH2O
HO

O
OH

19 µM

OH
OH

(2-18)
COOBr

Br

-O

O
Br

1.5 µM

48

O
Br
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2.11. Hypothesis on how cardiac glycoside’s inhibition of Na+/K+ ATPase leads to
inhibition of MDA-MB-231 breast cancer cell migration
2+

+

2+

The increase in [Ca ]i, through the activation of the reverse Na /Ca

exchanger
+

resulting from the “classical” inhibition of the ion transport function of the Na /K
+

+

+

ATPase, might explain the observed inhibitory activity of Na /K ATPase inhibitors in
2+

MDA-MB-231 breast cancer cell migration. Ca signaling is a crucial coordinator of cell
migration through various mechanisms. Some of these mechanisms include activation of
myosin light chain kinase (MLCK), modulation of nascent focal adhesions, and
retraction–adhesion of lamellipodia through local calcium pulses near the leading edge of
migrating cells51. Consequently, inhibition of key regulators of calcium homeostasis
affects cell migration. In the wound-closure assay, thapsigargin, a specific and
irreversible inhibitor of sarco/endoplasmic reticulum Ca

2+

ATPase (SERCA), inhibited

the migration of bovine aortic endothelial cells (BAEC). In this migrating BAEC,
2+

thapsigargin treatment elicited a rapid increase in [Ca ]i due to depletion of Ca

2+

store

sites52. Interestingly, through chemical genetic screening using the same wound-closure
assay, we found that thapsigargin 2-19 and an analog 2-20 inhibited MDA-MB-231
breast cancer cell migration below their cytotoxic concentration (Fig. 2-21). Besides
small molecule inhibition, it was reported that siRNA knockdown of SERCA and other
2+

key Ca regulators such as plasma membrane calcium ATPase (PMCA) and components
of store-operated Ca

2+

2+

(SOC) influx pathway also altered the basal [Ca ]i. An inverse
2+

correlation between the effect of small molecule and siRNA knockdown to [Ca ]i and
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2+

cell migration was observed, where an increase in [Ca ]i reduced the speed of human
umbilical vein endothelial cells (HUVECs) and vice versa51b. The aim of the present
study is to illustrate the utility of correlative SAR as a strategy to link a specific protein
function of a multifunctional protein to an observed cellular phenotype. Although the
+

+

+

+

2+

present study did not explore the effect of Na /K ATPase inhibitors in Ca

signaling,

we showed that the antimigratory effect of Na /K ATPase inhibitors in MDA-MB-231
breast cancer cell migration is directly related to inhibition of the ion-transport function
+

+

+

of the Na pump. It is established that this classical inhibition of Na /K ATPase leads to
2+

an increase in intracellular [Ca ]I33 and thus, it is possible that the observed
+

+

antimigratory effect of Na /K ATPase inhibitors in MDA-MB-231 breast cancer cells
2+

might be due to the increase in [Ca ]i, probably in a similar manner that thapsigargin
inhibited the migration of this cell line.
O

O

O
O

O

O
H

H

O

O

O

O
O
OH

O
O

OH
O

2-19 (tapsigargin)

O
OH

O
O

OH
O

2-20 (tapsogargin analog)

Fig. 2-21. Thapsigargin 2-19 and analog 2-20 were found to inhibit the migration of
MDA-MB-231 breast cancer cell from chemical genetic scre ening. Both 2-19 and 2-20
were toxic above 10 µM (Maximum Lethal Concentration) in MDA-MD-231 and have
antimigratory activity above 400 nM (Minimum Inhibitory Concentration).
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2.12

Conclusion
In this study, correlative SAR of cardiac glycosides and analogs were used to link
+

+

the ion transport function of Na /K ATPase to MDA-MB-231 breast cancer cell
migration. Analogs of representative cardiac glycosides ouabian and digitoxin that
contain modifications in each part of the tripartite cardiac glycoside were synthesized.
The effect of each structural modification on cardiac glycosides to their activities in both
+

+

inhibition of Na /K ATPase (molecular) and cell migration (cellular) provided a distinct
pattern (SAR profile). Our results showed that modification on steroid core >
modification on lactone ring > modification on sugar in decreasing impact on potency.
These SAR profiles correlated in both experimental assays, showing a direct relationship
between inhibition of MDA-MB-231 breast cancer cell migration and inhibition of
+

+

+

Na /K ATPase ion transport function. The interactions of ouabain and analogs to Na /K

+

ATPase were also investigated at the atomic level using molecular docking experiments.
+

+

Their activities in both inhibition of Na /K ATPase and cell migration correlated quite
well with the degree of similarity in orientation with respect to the known ouabian
orientation and reasonably well with binding energy calculations, provided that the
analog completely blocks the permeation path. A cardiac glycoside analog may have a
+

+

higher binding energy to Na /K ATPase, but if its orientation does not allow for
effective blocking of the ion permeation path, binding of that analog may not result in
efficient inhibition.
+

Based on these results, we conclude that it is the ion-transport function of Na /K

+
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ATPase that is involved in MDA-MB-231 breast cancer cell migration and not the
receptor function. This conclusion is further corroborated by the observed inhibition of
+

+

breast cancer cell migration by other Na /K ATPase inhibitors that are structurally
+

+

distinct from cardiac glycosides. In particular, a Na /K ATPase inhibitor that does not
+

+

activate Na /K ATPase/Src complexes nor the protein kinase cascades still inhibited cell
+

+

migration, implying that the antimigratory effect of Na /K ATPase inhibitors does not
involve activation of its receptor function. We speculate that a mechanism in which
+

+

+

perturbation of intracellular Na and K and therefore Ca ion concentrations leads to
inhibition of breast cancer cell migration. Further studies on how exactly perturbations of
ion homeostasis affect the migration of MDA-MB-231 cells could help contribute to
understanding the overall mechanism of triple negative breast cancer cell migration. This
report also provides an example of how correlative SAR can help establish new
relationships between specific biochemical functions and higher-level cellular processes
by providing a quantitative way to link the effect of small molecules at the cellular,
molecular, and atomic level.
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2.13 Experimental

Chemical genetic screening for MDA-MB-231 breast cell migration inhibitors

A previously published high-throughput protocol for screening of inhibitors of epithelial
cell sheet migration (ref) was adopted for chemical genetic screening (of around 12,000
natural products and synthetic compounds) of MDA-MB 231 breast cancer cell migration
inhibitors. MDA-MB 231 breast cancer cells were plated on 96-well tissue culture plates
and cultured at 37"°C and 5"% CO2 with Dulbecco's Modified Eagle Medium and 10%
FBS until confluent. Test compounds from the library (dissolved in DMSO) and DMSO
alone (as a control) were added with fresh medium to the confluent cell cultures at an
initial screening concentration of 50 µm (1% v/v DMSO/medium). We found that 1%
DMSO had no detectable effect on the migration or growth of MDA-MB 231 cells
compared to medium alone. After 30 min, the cell monolayers were scraped with a
micropipet tip to produce oval-shaped wounds of 0.5–1.0 mm2 in area. Progress of wound
closure was followed by observation on an inverted microscope at 12 h and 24 h. At each
time point, wounds were scored as either closed or opened realative to DMSO control to
determine possible inhibitory or acceleratory effects of the test compounds on wound
closure. Compounds that resulted in wounds that were still open after the wounds for the
control DMSO treatments were closed were considered antimigratory. Compounds that
were antimigratory at 50 µM were cherry-picked, pooled and screened again at lower
concentrations (10 µM, 2 µM, 400 nM and down to 16 nM) to gauge the compound’s
potency.
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Quantitative cell migration assay

Quantitative wound closure assay was performed on compounds that were active at sub
micromolar concentrations to evaluate their concentration-response profiles. Similar to
the primary wound closure assay, confluent monolayers of MDA-MB-231 breast cancer
cells were wounded 30 min after treatment with different concentrations of these
compounds or DMSO alone. Instead of a qualitative open or close wound evaluation, the
progress of the wound closure was followed quantitatively by taking digital images of the
wounds at 3 h, 6 h, 12 h and 24 h post-wounding. Using the NIH ImageJ software
( http://rsbweb.nih.gov/ij/), the remaining open area of the wound at each time point was
calculated by tracing the wound margin in each images. Microsoft Excel and GraphPad
Prism software were used to tabulate and analyze the corresponding data. GraphPad
Prism software was used to determine the IC50 for inhibition of wound closure from doseresponse data and two-tailed Student’s t-test (p > 0.05) was used to statistically determine
significant differences. Among the antimigratory compound hits from screening of
MDA-MB 231 breast cancer cell migration inhibitors, cardiac glycosides were chosen for
further characterization of their mechanism of action in relation to inhibition of MDAMB 231 breast cancer cell migration. Analogs of reperesentative cardiac glycosides,
ouabain and digitoxin were synthesized and analyzed for their effect on MDA-MB 231
breast cancer cell migration using the same quantitative cell migration assay.

163

Molecular Docking

A model of the complex between oubain bound sodium-potassium transporting ATPase
was obtained from the available crystallographic data at the RSCB website (4HYT) and
refined using Chimera GUI. Duplicate chains (C, D, and E) and chain G were deleted, as
they were not needed in the ligand docking. All residues were protonated based on
neutral pH after the assignment of bond orders using the Dock prep tool in Chimera.
Histidine tautomers were determined based on the ability to form Hydrogen bonds with
the neighboring residues. Ions, solvent molecules, extraneous molecules and substitution
codes for the side chains were also deleted.

The protein was assigned Amber force field parameters while antechamber was used to
assign the ligand and non-standard residues’ parameters. The charge set used for the
ligand was AM1-BCC charges; the structure was then minimized and duplicated – one
part had the ligand deleted (the receptor) while the other had the protein part deleted (the
ligand). The ligand was duplicated again one part was modified and minimized, while the
other served as a control.
Docking followed the standard docking procedure in the Dock6 manual. Molecular
surface was constructed using the dms program inbuilt in UCSF’s Chimera using a probe
radius of 1.4Å. The spheres were then generated using sphgen_cc implemented in Dock6
suite and the X-ray structure (reference) ligand was used to select the hotspot upto 10Å
from the position of the heavy atoms of the reference ligand. A site box and the generated
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spheres were then prepared using the showbox and showsphere modules. The grid box
enclosing the selected spheres had an extra 5Å added in every dimension. Grids were
computed using a grid spacing of 0.3A, distance dielectric of 4 with a combination of
contact and energy scores using the Van der Waals parameters of Amber99 force field.

Docking was performed through grid scoring and automated ligand orientation and
matching first with a rigid ligand then choosing 10 best poses and redocking while
keeping the ligand flexible. To account for receptor flexibility an ensemble docking was
attempted with Amber force field parameters and running a molecular dynamics
simulation; this instead did not give an improvement in the docking poses but produced
fluctuations in the structure. The final rescoring was done on the top most poses from the
grid score, using amber score (binding energy)
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In vitro Na+/K+ ATPase assay

The enzymatic activity of Na+/K+ ATPase (purchased from Sigma as lyophilized powder
from porcine cerebral cortex) was measured by colorimetric quantification of Pi released
during ATP hydrolysis. A previously published procedure47 was adapted with some
modifications. The reaction was started by incubating 10µL of Na+/K+ ATPase (600
units/mL) with 2.5 µL of KCl/NaCl solution (45mM KCl and 2M NaCl) at 37oC for 30
minutes with either 5 µL DMSO (control) or 5 µL test compounds in 67.5 µL buffer
(24mM Tris HCl buffer with 0.68 mM Ethylenediaminetetraacetic acid and 6.0 mM
Magnesium chloride, pH 7.8). 5µL of 80mM ATP was then added and the reaction
mixture was incubated again at 37oC for 15 minutes. 30 µL of 100% w/v Tricholoroacetic
acid was then added to the reaction mixture followed by centrifugation for 3 minutes.
50µL of the supernatant was transferred to a 96-well plate containing 100µL of TausskyShorr reagent. The absorbance at 660nm was read after incubation at room temperature
for 5 minutes. The concentration of phosphate released in the enzymatic reaction was
measured from the absorbance at 660nm using a standard curve. The effect of test
compounds on enzymatic activity (percent inhibition) was calculated by taking the ratio
of the concentration of liberated phosphate after compound treatment against that of
DMSO control. Dose-response (using 9 concentrations starting from 1mM to 15 nM) for
Na+/K+ ATPase inhibition was obtained for each test compounds for 3 trials with 3
replicates each trial. GraphPad Prism software was used to determine the IC50 for Na+/K+
ATPase inhibition from dose-response data and two-tailed Student’s t-test (p > 0.05) was
used to statistically determine significant differences. GraphPad Prism software was also

166

used to calculate and generate correlation plots for the inhibitory effect of test compounds
on the Na+/K+ ATPase enzymatic activity and MDA-MB 231 breast cancer cell migration
using Pearson correlation.
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Figure A-1. Dose-response curve for ouabain 2-8 effect in MDA-MB-231 wound closure.
IC50 values were determined by nonlinear regression analysis with GraphPad prism
software. It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by ouabain 2-8 is 173 nM.
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Figure A-2. Dose-response curve for ouabain 2-8 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by ouabain 2-8 is 105 nM.
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Figure A-3. Dose-response curve for ouabain 2-9 effect in MDA-MB-231
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wound

closure. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-9 is 790 nM.
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Figure A-4. Dose-response curve for ouabain 2-9 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-9 is 669 nM.
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Figure A-5. Dose-response curve for ouabain 2-10 effect in MDA-MB-231 wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-10 is 4.33 µM.
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Figure A-6. Dose-response curve for ouabain 2-10 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-10 is 2.6 µM.
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Figure A-7. Dose-response curve for 2-11 effect in MDA-MB-231 wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad prism software.
It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-11 is 30.9 µM.
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Figure A-8. Dose-response curve for ouabain 2-11 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-11 is 12.4 µM.
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Figure A-9. Dose-response curve for 2-12 effect in MDA-MB-231 wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad prism software.
It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-12 is 46 nM.
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Figure A-10. Dose-response curve for digitoxin 2-12 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-12 is 5.13 nM.
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Figure A-11. Dose-response curve for 2-13 effect in MDA-MB-231 wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad prism software.
It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-13 is 261 nM.
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Figure A-12. Dose-response curve for digitoxin 2-13 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-13 is 97 nM.
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Figure A-13. Dose-response curve for 2-14 effect in MDA-MB-231 wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad prism software.
It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-14 is 2.15 µM.
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Figure A-14. Dose-response curve for digitoxin 2-14 effect in in vitro Na+/K+ ATPase
inhibition. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated with normalization to DMSO control. The calculated
IC50 value for inhibition of the Na+/K+ ATPase activity by 2-14 is 691 nM.
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Figure A-15. Dose-response curve for 2-15a, 2-15b effects in MDA-MB-231 wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-15a, 2-15b is 10.8 µM.
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Figure A-16. Dose-response curve for digitoxin 2-15a, 2-15b effect in in vitro Na+/K+
ATPase inhibition. IC50 values were determined by nonlinear regression analysis with
GraphPad prism software. It was calculated with normalization to DMSO control. The
calculated IC50 value for inhibition of the Na+/K+ ATPase activity by 2-15a, 2-15b is 3.3
µM.
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Figure A-17. Dose-response curve for Na3VO4 2-16 effect in MDA-MB-231 wound
closure. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-16 is 5.6 µM.
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Figure A-18. Dose-response curve for Eosin 2-17 effect in MDA-MB-231

5

wound

closure. IC50 values were determined by nonlinear regression analysis with GraphPad
prism software. It was calculated for inhibition of wound closure at 24 h post-wounding
with normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by eosin 2-17 is 34.4 µM.
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Figure A-19. Dose-response curve for 2-18 effect in MDA-MB-231 wound closure. IC50
values were determined by nonlinear regression analysis with GraphPad prism software.
It was calculated for inhibition of wound closure at 24 h post-wounding with
normalization to parallel controls using at least 5 different subtoxic concentrations in
concentration-response experiments. The calculated IC50 value for inhibition of wound
closure at 24 h by 2-18 is 7.86 µM.
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Table A-1. Small molecule hits from chemical genetics screening of Analyticon natural
product compound library for inhibitors of MDA-MB-231 breast cancer cell migration

Structure

Plate number – Well number
Analyticon Code
Comments

P2-G3
NAT13-338106
Toxic at 50µM

P2-G4
NAT13-339685
Not toxic (still open after 48 hrs)

P2-H7
Not toxic (still wide open after 48
hrs)

P4-A10
NAT6-321371
Not toxic
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P5-D2
NAT13-339050
Toxic at 50µM

P5-E2
NAT-13338993
Toxic at 50µM

P5-E4
NAT-15-330225
Toxic at 50µM

P5-D3
NAT16-653195
Not toxic

P5-A5
NAT16-653195
Not toxic
P5-F4
Not toxic (still open after 48 hrs)
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P6-A6
NAT14-350403
MIC – 6.25 µM; MLC – 12.5 µM
Toxic at 50µM

P6-B6
NAT14-350423
MIC – 6.25 µM; IC50 – 5.8 µM;
MLC – 25 µM
Toxic at 50µM

P6-A10
NAT17-346996
Not toxic

P7-A3
NAT5-257066
Not toxic (still open after 48 hr)
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P7-A4
NAT15-330734
Not toxic (still open after 48 hr)

P7-B4
NAT15-330324
Not toxic (still open after 48 hr)

P8-A3
NP-009815
Not toxic

P8-A11
NP-004306
Toxic at 50 µM

P8-B6
NP-010071
Not toxic (still wide open after
48hrs)

P8-C8
NP-002767
Toxic at 50 µM
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P8-E2
NP-005313
Not toxic
P8-E4
NP-000518; cardiac glycoside
(ouabain) MIC – 61 nM; IC50 –
173 nM; MLC - >100µM
Not toxic at 50 µM (still wide
open after 48hrs)

P8-F4
NP-000192
Not toxic (still wide open after
48hrs)

P8-H11
NP-009822
Toxic at 50 µM

P9-H4
NP-005340; cardiac glycoside
Active from 2µM
Not toxic at 50µM (still wide open
after 48hrs)

P8-H11
NP-009822
Active from 400 nM
Toxic at 10 µM
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P9-E6
NP-001821
Toxic at 50 µM

P9-B10
NP-009784
Toxic at 50 µM

P9-B10
NP-009699
Toxic at 50 µM
P9-E10
NP-002481
Active from 80 nM
Not toxic at 50µM (still wide
open after 48hrs)
P9-G11
NP-008014
Toxic at 50 µM

P9-A5
NP-006205
Not toxic

P9-A11
NP-009051
Not toxic (still wide open after
48hrs)
P9-A11
NP-009051
Not toxic (slightly open after
48hrs)
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P9-C6
NP-003588
Toxic at 50 µM

P9-D7
NP-010664; colchicine
Active from 2µM
Not toxic at 50µM (still open after
48hrs)

P9-E9
NP-011363
Toxic at 50 µM

P10-G4
NP-012389
Not toxic (still wide open after
48hrs)

P10-H6
NP-012485
MIC – 1.5625 µM; IC50 – 3.8 µM;
MLC – 12.5 µM
Toxic at 50 µM

P10-G7
NP-004022
Not toxic (still wide open after
48hrs)
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P10-A8
NP-000424
MIC – 3.125 µM; IC50 – 5.9 µM;
MLC – 25 µM
Toxic at 50 µM

P10-D8
NP-007510
MIC – 3.125 µM; IC50 – 7.6 µM;
MLC – 25 µM
Toxic at 50 µM

P10-F8
NP-000423
Not toxic (still wide open after
48hrs)

P10-C9
NP-005099; cardiac glycoside
MIC - < 1.5625 µM; IC50 – 7.2
µM; MLC – 25 µM
Toxic at 50 µM
P10-C11
NP-008511; cardiac glycoside
MIC - < 1.5625 µM; IC50 – 5.4
µM; MLC – 5.4 µM
Toxic at 50 µM
P10-A5
NP-007572
Not toxic
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P10-E11
NP-012950
Not toxic (slightly open after
48hrs)

P11-F3
NP-012028
Not toxic (still wide open after
48hrs)
P11-G3
NP-006581
Toxic at 50 µM
P11-F7
NP-001595
Active from 400 nM
Toxic at 50, 10 µM

P11-H3
NP-008189
Toxic at 50 µM
P11-G4
NP-002480
Active from 2µM
Not toxic at 50µM (still wide open
after 48hrs)
P11-C5
NP-005331; curvularin
MIC – 3.125 µM; IC50 – 36 µM;
MLC - > 50µM
Not toxic at 50 µM (still wide
open after 48hrs)
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P11-F5
NP-012386
Not toxic (still wide open after
48hrs)

P4-G8
NAT3-210762
Not toxic
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